



Cochrane
Library

Cochrane Database of Systematic Reviews

Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults (Review)

Onwumeh J, Okwundu CI, Kredo T

Onwumeh J, Okwundu CI, Kredo T.

Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.

Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No.: CD009818.

DOI: 10.1002/14651858.CD009818.pub2.

www.cochranelibrary.com

Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults (Review)

Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	3
BACKGROUND	5
OBJECTIVES	5
METHODS	5
RESULTS	7
Figure 1.	8
Figure 2.	10
Figure 3.	11
Figure 4.	13
Figure 5.	14
Figure 6.	14
Figure 7.	15
Figure 8.	16
DISCUSSION	16
AUTHORS' CONCLUSIONS	17
ACKNOWLEDGEMENTS	17
REFERENCES	18
CHARACTERISTICS OF STUDIES	21
DATA AND ANALYSES	50
Analysis 1.1. Comparison 1 Interleukin-2 versus control, Outcome 1 All-cause mortality.	50
Analysis 1.2. Comparison 1 Interleukin-2 versus control, Outcome 2 HIV RNA levels < 50 cells/mL.	51
Analysis 1.3. Comparison 1 Interleukin-2 versus control, Outcome 3 HIV RNA levels < 500 cells/mL.	52
Analysis 1.4. Comparison 1 Interleukin-2 versus control, Outcome 4 Opportunistic infections.	53
Analysis 1.5. Comparison 1 Interleukin-2 versus control, Outcome 5 Adverse events (grade 3 or 4).	54
ADDITIONAL TABLES	54
APPENDICES	63
CONTRIBUTIONS OF AUTHORS	67
DECLARATIONS OF INTEREST	67
SOURCES OF SUPPORT	67
INDEX TERMS	67

[Intervention Review]

Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults

Jennifer Onwumeh¹, Charles I Okwundu^{2,3}, Tamara Kredo³

¹Community Health Division, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa. ²Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. ³Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa

Contact address: Jennifer Onwumeh, Community Health Division, Faculty of Health Sciences, Stellenbosch University, Cape Town, 7505, South Africa. dums_in_god@yahoo.com.

Editorial group: Cochrane Infectious Diseases Group.

Publication status and date: New, published in Issue 5, 2017.

Citation: Onwumeh J, Okwundu CI, Kredo T. Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults. *Cochrane Database of Systematic Reviews* 2017, Issue 5. Art. No.: CD009818. DOI: 10.1002/14651858.CD009818.pub2.

Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. This is an open access article under the terms of the [Creative Commons Attribution-Non-Commercial](#) Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

ABSTRACT

Background

Human immunodeficiency virus (HIV) continues to be a leading cause of morbidity and mortality, particularly in sub-Saharan Africa. Although antiretroviral drugs have helped to improve the quality of life and life expectancy of HIV-positive individuals, there is still a need to explore other interventions that will help to further reduce the disease burden. One potential strategy is the use of interleukin-2 (IL-2) in combination with antiretroviral therapy (ART). IL-2 is a cytokine that regulates the proliferation and differentiation of lymphocytes and may help to boost the immune system.

Objectives

To assess the effects of interleukin-2 (IL-2) as an adjunct to antiretroviral therapy for HIV-positive adults.

Search methods

We searched the following sources up to 26 May 2016: the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE; Embase; the Web of Science; LILACS; the World Health Organization (WHO) International Clinical Trial Registry Platform (ICTRP); and ClinicalTrials.gov. We also checked conference abstracts, contacted experts and relevant organizations in the field, and checked the reference list of all studies identified by the above methods for any other potentially eligible studies.

Selection criteria

Randomized controlled trials (RCTs) that evaluated the effects of IL-2 as an adjunct to ART in reducing the morbidity and mortality in HIV-positive adults.

Data collection and analysis

Two review authors independently screened records and selected trials that met the inclusion criteria, extracted data, and assessed the risk of bias in the included trials. Where possible, we compared the effects of interventions using risk ratios (RR), and presented them with 95% confidence intervals (CI). We assessed the overall certainty of the evidence using the GRADE approach.

Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults (Review)

Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

1

Main results

Following a comprehensive literature search up to 26 May 2016, we identified 25 eligible trials. The interventions involved the use of IL-2 in combination with ART compared with ART alone. There was no difference in mortality apparent between the IL-2 group and the ART alone group (RR 0.97, 95% CI 0.80 to 1.17; 6 trials, 6565 participants, *high certainty evidence*). Seventeen of 21 trials reported an increase in the CD4 cell count with the use of IL-2 compared to control using different measures (21 trials, 7600 participants). Overall, there was little or no difference in the proportion of participants with a viral load of less than 50 cells/mL or less than 500 cells/mL by the end of the trials (RR 0.97, 95% CI 0.81 to 1.15; 5 trials, 805 participants, *high certainty evidence*) and (RR 0.96, 95% CI 0.82 to 1.12; 4 trials, 5929 participants, *high certainty evidence*) respectively. Overall there may be little or no difference in the occurrence of opportunistic infections (RR 0.79, 95% CI 0.55 to 1.13; 7 trials, 6141 participants, *low certainty evidence*). There was probably an increase in grade 3 or 4 adverse events (RR 1.47, 95% CI 1.10 to 1.96; 6 trials, 6291 participants, *moderate certainty evidence*). None of the included trials reported adherence.

Authors' conclusions

There is high certainty evidence that IL-2 in combination with ART increases the CD4 cell count in HIV-positive adults. However, IL-2 does not confer any significant benefit in mortality, there is probably no difference in the incidence of opportunistic infections, and there is probably an increase in grade 3 or 4 adverse effects. Our findings do not support the use of IL-2 as an adjunct to ART in HIV-positive adults. Based on our findings, further trials are not justified.

PLAIN LANGUAGE SUMMARY

Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults

Why did we do this review?

HIV is still a major cause of death worldwide, particularly in Africa. HIV multiplies in the blood and damages the immune system. Therefore if HIV-positive, one is more vulnerable to contract infections. The current drug treatment, antiretroviral therapy (ART), stops the virus from multiplying thereby allowing the body's immune system to recover. Interleukin-2 (IL-2) is a protein in the body which helps the process of multiplication of white blood cells which are the cells that fight infections. Although IL-2 increases the amount of white cells we do not know if by increasing these we can add additional benefits to the use of ART alone. The aim of this Cochrane Review was to find out if using an extra treatment with antiretroviral therapy (ART), namely IL-2, compared to using ART alone can reduce illness and death in HIV-positive adults.

Key messages

We found that IL-2 causes an increase in the CD4 immune cells (*high certainty evidence*). However, there is no difference in important effects such as death and other infections (*high certainty evidence*). There is probably an increase in side-effects for those people using IL-2 (*moderate certainty evidence*). Our findings do not support further use of IL-2 as an add-on treatment to ART in HIV-positive adults.

Main results

After conducting a comprehensive search on 26 May 2016, we included 25 eligible trials conducted in six countries. There was no difference in the number of deaths between the IL-2 group and those that got ART alone (6 trials, 665 participants, *high certainty evidence*). Seventeen of 21 trials reported an increase in the CD4 cell count with the use of IL-2 compared to ART alone using different measures. Overall, there was no difference in the proportion of participants with a suppressed viral load of less than 50 cells/mL (5 trials, 805 participants, *high certainty evidence*) or less than 500 cells/mL by the end of the trials (4 trials, 5029 participants, *high certainty evidence*). Overall there may be little or no difference in the incidence of opportunistic infections (7 trials, 6141 participants, *low certainty evidence*). There was probably an increase in grade 3 or 4 adverse events (6 trials, 6291 participants, *moderate certainty evidence*). None of the included trials reported on adherence.

SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

Interleukin-2 compared to control for HIV-positive adults						
Patient or population: HIV-positive adults Settings: high- and middle-income settings Intervention: interleukin-2 (IL-2) plus antiretroviral therapy (ART) Comparison: ART alone						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	Number of participants (trials)	Certainty of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	IL-2				
All-cause mortality	60 per 1000	58 per 1000 (48 to 70)	RR 0.97 (0.80 to 1.17)	6565 (6 trials)	⊕⊕⊕⊕ high	There is little or no effect on all cause mortality
CD4 cell count	Tended to increase in all but one study			7600 (21 trials)	-	Tended to increase in all but one study
HIV RNA levels less than 50 cells/mL	636 per 1000	617 per 1000 (515 to 732)	RR 0.97 (0.81 to 1.15)	805 (5 trials)	⊕⊕⊕⊕ high	There is little or no effect on viral suppression
HIV RNA levels less than 500 cells/mL	81 per 1000	77 per 1000 (66 to 90)	RR 0.96 (0.82 to 1.12)	5929 (4 trials)	⊕⊕⊕⊕ high	
Opportunistic infections	46 per 1000	39 per 1000 (26 to 54)	RR 0.79 (0.55 to 1.13)	6141 (7 trials)	⊕⊕○○ low ¹	There may be little or no effect on opportunistic infections
Adverse events (grade 3 or 4)	197 per 1000	242 per 1000 (193 to 303)	RR 1.47 (1.10 to 1.96)	6291 (6 trials)	⊕⊕⊕○ moderate ²	There is probably an increase in adverse events

*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

Abbreviations: CI: confidence interval; RR: risk ratio.

GRADE Working Group grades of evidence

High certainty: further research is very unlikely to change our confidence in the estimate of effect.

Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low certainty: we are very uncertain about the estimate.

¹Downgraded by 2 for imprecision due to low event rate resulting in a wide 95% CI is wide. The overall meta-analysis remains underpowered to confidently exclude effects.

²Downgraded by 1 for imprecision.

BACKGROUND

Description of the condition

Human immunodeficiency virus (HIV) continues to be a major cause of morbidity and mortality globally (UNAIDS 2016). In 2015 there were 2.1 million people newly diagnosed as HIV-positive with almost half of those from Southern and Eastern Africa (UNAIDS 2016). In addition to the decrease in life expectancy caused by the disease, there are substantial health costs that may impact on the economy of affected countries. This has all led to strategic efforts by world leaders and researchers to discover effective treatments for the condition and thus curtail loss of life and the related social and economic burden (UNAIDS 2016).

HIV harms the body's immune system, particularly the CD4 lymphocytes. It destroys the host immune system, making it susceptible to opportunistic infections (Grimwade 2009; Harari 2004). Though various interventions have helped to improve the quality of life and life expectancy of HIV-positive individuals, interventions are needed that will alleviate the effects of the disease by restoring the immune system (Harari 2004). For instance, following the introduction of antiretroviral therapy (ART) including at least three antiretroviral agents, the treatment of HIV infection is highly potent and fairly well tolerated but not without limitations (Nachega 2011). ART, which is currently the mainstay of treatment, inhibits viral replication and does not reconstitute the immune system directly (Blankson 2000; Piliero 2003). Many HIV-positive adults do not achieve normal CD4 counts despite suppressing viral replication (Pett 2010).

Long-term ART use is associated with drug-resistant HIV strains, as well as cumulative drug-related toxicities, including abnormalities in substrate metabolism (Piliero 2003). In addition, prolonged ART exposure may result in adherence fatigue and increased morbidity. This has encouraged the exploration of novel strategies to reduce the infection by augmenting the immune system and if possible completely reconstituting the immune system (Horn 2002). One such novel potential strategy has been the use of interleukin-2 (IL-2) as an adjunct with ART (Horn 2002).

Description of the intervention

IL-2 is a cytokine that regulates the proliferation and differentiation of lymphocytes. Cytokines are immunological proteins produced by lymphocytes which work to expand the pool of immunological cells and mobilize latent reservoirs of such cells in people with HIV and other infections (Pett 2001). IL-2 is a T-cell growth factor produced predominantly by CD4+ T-cells (Pett 2001). Its production is decreased in HIV-positive participants (Abrams 2009). A synthetic version of the protein has been produced as proleukin. It is an important factor in the proliferation of CD4 T lymphocytes, which is a major target of HIV (Pett

2010). It is also useful in the differentiation of CD4 and CD8 cells, natural killer cells, and macrophages (Horn 2002). These cells are depleted in HIV-positive participants, and therefore there has been this interest in the use of IL-2 as an adjuvant therapy in the treatment of HIV-positive individuals (Horn 2002). The low dose formulation of proleukin is rarely known to cause side effects and appears to be well-tolerated (Horn 2002). Earlier studies reported that, by helping the reconstitution of the immune system, IL-2 may help to defer the commencement of ART in certain participants by up to 48 weeks (Molina 2007). However, little is known about its interaction with ART and the potential toxicities in adults, children, and unborn babies (Horn 2002).

How the intervention might work

IL-2 may work by increasing the CD4 cell count and therefore assisting to reconstitute the immune system, and help in the control of viral replication thereby boosting the effect of ART (Horn 2002). By priming the immune system it might help protect it from the damage caused by HIV and lead to lower susceptibility to opportunistic infections (Horn 2002).

Why it is important to do this review

If there is proven benefit of using IL-2 as an adjunct in terms of decreased viral load and adverse effects, increased CD4 counts, and other patient-related important outcomes, there will be value in introducing the use of IL-2 more systematically as a treatment adjunct aiming for an overall improvement in morbidity and mortality. This review aims to summarize the available evidence from randomized controlled trials (RCTs) on the use of IL-2 as an adjunct to ART in the treatment of HIV-positive participants.

OBJECTIVES

To assess the effects of interleukin-2 (IL-2) as an adjunct to antiretroviral therapy (ART) for HIV-positive adults.

METHODS

Criteria for considering studies for this review

Types of studies

Randomized controlled trials (RCTs).

Types of participants

Adults who were 18 years old and above, diagnosed as seropositive for HIV on finger prick or laboratory blood testing and eligible to receive antiretroviral treatment (ART).

These included ART-naïve (no prior ART exposure) and ART-experienced (previously treated or currently on ART) participants. The safety of interleukin-2 (IL-2) in children is not yet proven.

Types of interventions

IL-2 and any combination of ART.

Variations of interest included IL-2 co-administered with antiretroviral monotherapy or with dual therapy or with the standard recommended three drug regimens.

We included any dose of IL-2 for this review.

Types of outcome measures

Primary outcomes

- All-cause mortality.

Secondary outcomes

- Change in CD4 cell count.
- Proportion of participants with undetectable viral load at any time point after initiation of IL-2.
- Opportunistic infections.
- Adherence (as measured by the trial authors).
- Adverse events.

Search methods for identification of studies

Electronic searches

We formulated a comprehensive and exhaustive search strategy in order to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and in progress).

Journals and trial databases

We searched the following electronic databases from 1980 up to 26 May 2016.

- The Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library ([Appendix 1](#)).
- MEDLINE ([Appendix 2](#)).
- Embase ([Appendix 3](#)).

Along with MeSH terms and relevant keywords, we used the Cochrane Highly Sensitive Search Strategy for identifying reports

of RCTs in MEDLINE ([Higgins 2008a](#)). We also searched references of included studies for other potentially relevant studies. Using a variety of relevant terms, we also searched ClinicalTrials.gov (www.clinicaltrials.gov; [Appendix 4](#)) and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<http://apps.who.int/trialsearch/>) for any ongoing trials.

Searching other resources

Conference abstract databases

We planned to search Aegis archive of HIV/AIDS conference abstracts (www.aegis.org). However, this database is no longer functional and was not searched.

We did search the CROI and International AIDS Society websites for abstracts presented at conferences subsequent to those listed above using different combinations of relevant search terms, such as antiretroviral, interleukin-2, HIV, viral load, therapy, CD4 count, and other terms in combination. We contacted experts and relevant organizations in the field to identify any other potentially eligible studies, including unpublished and ongoing trials.

Data collection and analysis

Selection of studies

Two review authors (JO and CO) independently screened the titles and abstracts of the literature search results to identify potentially eligible studies. We resolved any discrepancies through discussion. We obtained the full-text articles of all potentially eligible articles in order to formally assess eligibility using the prespecified eligibility criteria. If there was ambiguity we sought clarification from the study authors. We listed all excluded studies and their reasons for exclusion in a 'Characteristics of excluded studies' table. We also presented the study selection process in a PRISMA diagram.

Data extraction and management

Two review authors (JO and CO) independently extracted data from the included trials using a detailed data extraction form. We extracted the following information.

- Study details: citation, start and end dates, location, study design, and details.
- Participant details: study population eligibility (inclusion and exclusion) criteria, ages, population size, and attrition rate.
- Details about the interventions: dose, duration of treatment, concomitant antiretroviral treatment (ART) regimens.
- Details of the outcomes: CD4 cell count, viral load, death, adverse effects, and adherence.

For each dichotomous outcome, we extracted the number of participants experiencing the event and the number of participants in

each treatment group. For each continuous outcome we extracted the mean or geometric mean values and standard deviations (SDs) (or information to estimate the SDs) for each treatment group, together with the numbers of participants in each group. We also extracted the median and range values if these were reported in place of mean and SDs values.

Assessment of risk of bias in included studies

Two review authors (JO and CO) performed the 'Risk of bias' assessments independently using the Cochrane 'Risk of bias' assessment tool (Higgins 2008b). The Cochrane approach assesses risk of bias in individual studies across the following six domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential biases.

We resolved any differences in opinion through discussion. We presented the 'Risk of bias' assessments for individual trials in the 'Risk of bias' tables, and also in a 'Risk of bias' summary and 'Risk of bias' graph.

Measures of treatment effect

For dichotomous outcomes, we used risk ratios (RRs) to measure treatment effect. For continuous outcomes, we presented the mean or median and SD values or ranges. We presented RRs and mean differences with 95% confidence intervals (CIs).

Unit of analysis issues

All included trials were RCTs and we analysed the data at the level of the individual.

Dealing with missing data

We did not apply any imputation measures for missing data as there were no missing data. We planned to contact authors for missing data, but this was not required.

Assessment of heterogeneity

We assessed statistical heterogeneity by visually inspecting the forest plots to detect overlapping confidence intervals, applying the Chi^2 test (P value < 0.10 considered statistically significant), and also by using the I^2 test statistic to evaluate the degree of heterogeneity.

Assessment of reporting biases

Funnel plots describe the relationship between the standard error and the effect size and provide a graphic display of potential reporting bias. We had planned to evaluate reporting bias by assessing the symmetry of a funnel plot. However, as the recommended 10 study minimum was not met for any of the outcomes, we did not proceed with the funnel plot assessment.

Data synthesis

We analysed data using Review Manager 5 (RevMan 5) software (Review Manager 5), and conducted meta-analysis using the random-effects model. We assessed the certainty of the evidence across each outcome measure by using the GRADE approach. The certainty rating across studies has four levels: high, moderate, low, or very low certainty but can be downgraded after assessment of five criteria: risk of bias, consistency, indirectness, imprecision, and publication bias. Similarly, observational studies are initially categorized as low certainty and can be downgraded by these same criteria. In exceptional circumstances they may be upgraded by three further criteria: large effect size, all plausible confounders would act to reduce the effect size, and evidence of a dose-response effect (Guyatt 2008)

Subgroup analysis and investigation of heterogeneity

We performed a subgroup analysis based on whether the participants were ART experienced or ART naive.

Sensitivity analysis

Several studies had unclear risk of bias due to unclear reporting on allocation concealment, but this was not adequate to prompt a sensitivity analysis based on the trial quality.


RESULTS

Description of studies

Results of the search

We performed electronic literature searches up to 26 May 2016. We identified a total of 1007 records, which we screened by title/abstract. We identified 35 potentially eligible studies and obtained the full-text articles of these studies. We excluded 10 studies, which we listed along with their reasons for exclusion in the 'Characteristics of excluded studies' table. Twenty-five trials met the inclusion criteria of the review. We have presented the study selection process in a PRISMA flow diagram (Figure 1).

Figure 1. Study flow diagram



Included studies

See the 'Characteristics of included studies' and Table 1, which further describe the populations and interventions in the included trials.

Study design and setting

We included 25 parallel-design RCTs in the review (Abrams 2002; Abrams 2009a; Abrams 2009b; Amendola 2000; Caggiari 2001; Carr 1998; Davey 2000; de Boer 2003; Dybul 2002; Hengge 1998; Katlama 2002; Kelleher 1998; Kovacs 1996; Lalezari 2000; Levy 1999; Levy 2003; Losso 2000; Marchetti 2002; Marchetti 2004; Mitsuyasu 2007; Ruxrungham 2000; Stellbrink 2002; Tambussi 2001; Tavel 2003; Vogler 2004).

Eleven trials were conducted in academic centres in the USA (Abrams 2002; Davey 2000; Dybul 2002; de Boer 2003; Abrams 2009a; Abrams 2009b; Kovacs 1996; Lalezari 2000; Mitsuyasu 2007; Tavel 2003; Vogler 2004). The other 14 included trials were conducted in Argentina (Losso 2000), France (Katlama 2002; Levy 1999; Levy 2003), Italy (Amendola 2000; Caggiari 2001; Marchetti 2002; Marchetti 2004; Tambussi 2001), Australia (Carr 1998; Kelleher 1998), Germany (Hengge 1998; Stellbrink 2002), and Thailand (Ruxrungham 2000).

Participants

All participants were HIV-positive adults either ART experienced or who were commenced on ART during the trial, with CD4 cell counts of at least 50 cells/mm³. The number of participants per trial ranged from nine participants (Dybul 2002), to 4111 participants (Abrams 2009a).

Interventions

In all included trials, participants in the intervention group received IL-2 and ART, while those in the control group received ART alone. The dose of IL-2 and the ART regimen varied across the included trials. Some trials compared doses of either 4.5 miu of IL-2, 7.5 miu of IL-2 with ART, or different subgroups of both doses with the control group (Abrams 2002; Abrams 2009a; Abrams 2009b; Davey 2000). Some trials had three trial arms that compared different routes of administration, including subcutaneous versus intravenous administration with the control group (ART alone) (Carr 1998; Mitsuyasu 2007; Tambussi 2001). Other included trials had three trial arms that compared IL-2, a control group, and different modified forms of IL-2, such as polyethylene glycol (PEG) modified IL-2 (Carr 1998; Kelleher 1998; Levy 1999), and granulocyte stimulating factor-modified IL-2 (Amendola 2000), and prednisone-modified IL-2 (Vogler 2004).

Outcomes

Of the outcomes of interest in this Cochrane Review, the included trials reported the following outcomes: all-cause mortality, change in CD4 cell, viral load, opportunistic infections, and adverse effects. However, none of the included trials reported on adherence.

Excluded studies

After considering the full-text articles, we excluded 10 potentially eligible studies that did not meet our inclusion criteria. We have provided the reasons for excluding these trials in the 'Characteristics of excluded studies' table.

Risk of bias in included studies

We have provided a graphical summary of the 'Risk of bias' assessment results (Figure 2; Figure 3).

Figure 2. 'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials




Figure 3. 'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Abrams 2002	+	+	+	+	+	+	+
Abrams 2009a	+	+	+	+	+	+	+
Abrams 2009b	+	+	+	+	+	+	+
Amendola 2000	?	?	+	+	?	+	+
Caggiari 2001	?	?	+	+	?	+	+
Carr 1998	?	?	+	+	+	+	-
Davey 2000	+	+	+	+	+	+	+
de Boer 2003	+	+	+	+	+	+	+
Dybul 2002	?	?	+	+	?	+	+
Hengge 1998	-	-	+	+	+	+	+
Katlama 2002	+	+	+	+	+	+	+
Kelleher 1998	?	?	+	+	+	+	+
Kovacs 1996	?	?	+	+	+	+	+
Lalezari 2000	+	+	+	+	-	+	+
Lewy 1999	?	?	+	+	+	+	+
Lewy 2003	+	+	+	+	+	+	+
Losso 2000	+	+	+	+	+	+	-
Marchetti 2002	?	?	+	+	+	+	+
Marchetti 2004	?	?	+	+	+	+	+
Mitsuyasu 2007	+	?	+	+	-	+	+
Ruxrungtham 2000	+	?	+	+	?	+	+
Stellbrink 2002	?	?	+	+	+	+	+
Tambussi 2001	?	?	+	+	+	+	-
Tavel 2003	?	?	+	+	?	+	+
Vogler 2004	?	?	+	+	+	+	+

Allocation

Random sequence generation

There was adequate sequence generation in 11 of the 25 included trials (Abrams 2002; Abrams 2009a; Abrams 2009b; Davey 2000; de Boer 2003; Katlama 2002; Lalezari 2000; Levy 2003; Losso 2000; Mitsuyasu 2007; Ruxrungtham 2000). There was high risk of selection bias in Hengge 1998. The remaining 13 included trials poorly reported the method of sequence generation.

Allocation concealment

More than half of included studies did not report allocation concealment clearly and were judged as having unclear risk of bias. One study, Hengge 1998, had high risk of allocation concealment bias due to the manner in which participant selection was conducted.

Blinding

The included trials were open label trials with no blinding of participants. However, all of the reported outcome measures are objective. Therefore we judged each of the included trials as at low risk of bias regarding blinding.

Incomplete outcome data

We considered the following trials to have a low risk of attrition bias with low or minimal loss to follow-up: Abrams 2002; Abrams 2009a; Abrams 2009b; Carr 1998; Davey 2000; de Boer 2003; Hengge 1998; Katlama 2002; Kelleher 1998; Kovacs 1996; Levy 1999; Levy 2003; Losso 2000; Marchetti 2002; Marchetti 2004; Stellbrink 2002; Tambussi 2001; and Vogler 2004. There was high risk of attrition bias in Lalezari 2000 and Mitsuyasu 2007. Five trials had unclear risk of attrition bias (Amendola 2000; Caggiari 2001; Dybul 2002; Ruxrungtham 2000; Tavel 2003).

Selective reporting

All included trials were at low risk of selective reporting bias. The trials reported all outcomes that they described in the methods in the results.

Other potential sources of bias

We identified other potential sources of bias in the following three trials (Carr 1998; Losso 2000; Tambussi 2001). In Carr 1998, there was potential for both detection bias or performance bias due to the fact that the IL-2 group were hospitalized for five to six days longer than the control group. However, as the outcomes reported are considered objective (i.e. CD4 count and viral load) the potential risk is probably low. Losso 2000 had more monitoring in the IL-2 group than in the control group, which caused a potential for detection bias and performance bias since some adverse effects could be subjective. There was a high risk of performance bias in Tambussi 2001 due to differential treatment. Participants who were randomized to the continuous intravenous high dose and subcutaneous high dose groups received the first two cycles of IL-2 as inpatients and the following cycles on an outpatient basis, whereas participants in the low dose and control groups were followed up as outpatients from the beginning of the trial.

Effects of interventions

See: [Summary of findings for the main comparison 'Summary of findings' table 1](#)


See [Summary of findings for the main comparison](#).

Primary outcomes

All-cause mortality

Eight trials reported on all-cause mortality (Abrams 2002; Abrams 2009a; Abrams 2009b; Kovacs 1996; Levy 1999; Losso 2000; Mitsuyasu 2007; Vogler 2004). Trials reported mortality at six months (Vogler 2004), 12 months (Abrams 2002), 13 months (Levy 1999), 14 months (Kovacs 1996), 20 months (Mitsuyasu 2007), and seven years (Abrams 2009b; Abrams 2009a). Levy 1999 and Mitsuyasu 2007 had more than two trial arms, which we did not include in the pooled analysis. Therefore, we pooled results from six trials (Abrams 2002; Abrams 2009a; Abrams 2009b; Kovacs 1996; Losso 2000; Vogler 2004) (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.80 to 1.17; 6 trials, 6565 participants, *high certainty evidence*; Analysis 1.1; Figure 4). There was no significant difference in the test for subgroup differences looking at ART experienced participants and others (ART naive or experienced or unclear ART status). We also did not find any significant subgroup differences with trials that reported the outcome at seven years and those that reported the outcome at less than 24 months.

Figure 4.



Secondary outcomes

Change in CD4 cell count

Twenty-one trials reported on change in CD4 cell count: (Abrams 2002; Abrams 2009a; Abrams 2009b; Amendola 2000; Carr 1998; Davey 2000; de Boer 2003; Dybul 2002; Hengge 1998; Katlama 2002; Kovacs 1996; Lalezari 2000; Levy 1999; Levy 2003; Losso 2000; Marchetti 2002; Mitsuyasu 2007; Tambussi 2001; Tavel 2003; Ruxrungtham 2000; Vogler 2004).

We did not pool the results because the included trials reported either means or median values differently (see Table 2 which describes the different reporting on CD4 count changes by the included trials).

Significant increase in CD4 cell count with IL-2

Fifteen trials reported a significant increase in CD4 cell count in the group assigned to IL-2 treatment (Abrams 2002; Carr 1998; Davey 2000; de Boer 2003; Hengge 1998; Katlama 2002; Kovacs 1996; Lalezari 2000; Levy 1999; Levy 2003; Losso 2000; Marchetti 2002; Mitsuyasu 2007; Tavel 2003; Ruxrungtham 2000).

Increase in CD4 cell count but statistical significance not reported

Five trials provided results for a relative increase in CD4 count in the groups receiving IL-2. Abrams 2009a reported this outcome at seven years; Abrams 2009b and Amendola 2000 reported at six months; Dybul 2002 and Tambussi 2001 reported this at 84 weeks. However, these trials did not provide further details of whether the difference was statistically significant.

No significant increase in CD4 cell count

Two trials reported that there was no significant difference in the CD4 cell count between groups over 24 weeks, Ruxrungtham 2000 and Vogler 2004; however in the Ruxrungtham 2000 trial the lack of difference depended on the dosing of IL-2 with higher doses resulting in a significant difference in a dose-response manner.


Proportion of participants with undetectable viral load at any time point

Plasma viral load less than 50 copies/mL

Seven trials reported on viral load of less than 50 copies/mL (Abrams 2002; Davey 2000; Lalezari 2000; Levy 2003; Marchetti 2002; Mitsuyasu 2007; Tavel 2003). None of the included trials found any significant difference between the two groups irrespective of the time when the viral load was measured. Overall, in the pooled analysis, there was no significant difference in the proportion of participants with a viral load of less than 50 copies/mL by

the end of the trials (RR 0.97, 95% CI 0.81 to 1.15; 5 trials, 805 participants, *high certainty evidence*; Analysis 1.2; Figure 5).


Figure 5.



Plasma viral load level less than 500 copies/mL

Four trials reported on plasma viral load of less than 500 copies/mL (Abrams 2009a; Abrams 2009b; Levy 1999; Losso 2000). None of the included trials found any significant difference between the two groups in viral load of less than 500 copies/mL irrespective of the time when the viral load was measured. The overall results did not show any significant difference in the two groups (RR 0.96, 95% CI 0.82 to 1.12; 4 trials, 5929 participants, *high certainty evidence*; Analysis 1.3; Figure 6).

Figure 6.



Undetectable viral loads

In Amendola 2000, participants in both groups had HIV load levels below detection limit at the end of the study. Caggiari 2001 reported undetectable viral loads in six out of seven participants both the IL-2 and ART only group. Carr 1998 did not report any difference in the mean viral load in any of the study arms. In Kovacs 1996, there were no significant differences between the

groups in serial measurements of the plasma viral load or p24 antigen concentration during the 12 months of treatment.

Other viral load measurements


Six included trials found no significant difference in viral load (Hengge 1998; Katlama 2002; Levy 2003; Marchetti 2002;

Tambussi 2001; Vogler 2004).

Opportunistic infections

Seven included trials reported the incidence of opportunistic infections (Abrams 2009a; Abrams 2009b; Carr 1998; Hengge 1998; Katlama 2002; Kovacs 1996; Mitsuyasu 2007). Overall there was no significant difference between the two groups (RR 0.79, 95% CI 0.55 to 1.13; 7 trials, 6141 participants, *low certainty evidence*; Analysis 1.4; Figure 7).

Figure 7.



Adherence

None of the included trials reported on adherence.

Adverse events

Nine included trials reported on adverse events (Abrams 2009a; Abrams 2009b; Davey 2000; de Boer 2003; Katlama 2002; Lalezari 2000; Levy 2003; Marchetti 2002; Tavel 2003).

GRADE 3 or higher adverse events

In Abrams 2009a, a total of 203 participants receiving IL-2 and 186 participants in the control group had a grade 4 adverse event.


In Abrams 2009b, a total of 203/849 participants receiving IL-2 and 186/846 participants in the control group had a grade 4 adverse event. Davey 2000 reported grade 3 or higher adverse events in 20/39 participants in the IL-2 group and in 7/43 adverse events in the control group (RR 3.13, 95% CI 1.50 to 6.63). Lalezari 2000 reported grade 3 adverse events in 10/56 participants (18%) in the IL-2 group and in 9/59 (15%) of the control group while grade 4 adverse events were 1 (2%) and 3 (5%) respectively. Levy 1999 reported that severe adverse effects, such as aspartate transaminase deficiency, were reported in 2/26 of the participants in the control group and 16 participants (25%), 2 participants (5%), and 4 participants (9%), in the subcutaneous, PEG-modified, and intravenous IL-2 groups respectively. Severe neutropenia

(less than 1×10^9 /mL) was also seen in 2/26 (8%) participants in the control group and 9 participants (8%), 2 participants (9%), 3 participants (4.5%) in the subcutaneous, PEG-modified, and intravenous IL-2 groups. Levy 2003 reported that grade 3 or 4 adverse effects were noted in 34/53 participants (64%) in the IL-2 group compared to 12/56 participants (22%) in the control group ($P < 0.001$).

In Mitsuyasu 2007, both IL-2 arms were associated with significantly more grade 3 or 4 clinical toxic effects usually associated with IL-2 treatment (with values of 30%, 53%, and 67% for 57, 58, and 59 participants) in the ART only, intravenous IL-2 group,

and subcutaneous IL-2 group respectively. Tavel 2003 reported episodes of severe toxicities, neutropenia, and orthostatic blood pressure respectively in 2/5 participants compared to 0/4 in the control participants. Vogler 2004 reported no statistical significant difference between both groups in grade 3 or worse adverse effects ($P \geq 0.12$). By the end of the trial at 24 weeks, two grade 4 events had occurred: one case of grade 4 hypertriglyceridaemia, one case of agitation in the ART plus IL-2 group, and none in the control. Overall there were greater adverse effects in those participants receiving IL-2 (RR 1.47, 95% CI 1.10 to 1.96; six trials, 6291 participants, *moderate certainty evidence*; Analysis 1.5; Figure 8).

Figure 8.



GRADE 2 or lower adverse events

In Lalezari 2000, grade 2 or lower adverse events were reported in 43/56 participants in the IL-2 group and in 47/59 of the control group. Katlama 2002 reported that all participants receiving IL-2 experienced at least one mild-to-moderate side-effect, mainly constitutional symptoms such as fever, fatigue, malaise, and myalgias. Marchetti 2002 reported lower than grade 3 events in a total of 11 participants. Mild constitutional symptoms, such as fever (grade 1 to 2), fatigue, and myalgia were experienced by 10/12 participants receiving IL-2, a reversible localized erythematous nodule at the site of injection was observed in 11/12 participants.

DISCUSSION

Summary of main results

We identified 25 trials that met our inclusion criteria. The number of participants in the included trials varied from nine to 4111 participants. Interleukin-2 (IL-2) doses and the duration of follow-up varied across the included trials. We judged the risk of bias due

to methodological quality of the included studies to be low. There was no significant difference in mortality whether IL-2 was added to the ART regimen or not (*high certainty evidence*). There was a significant increase in CD4 cell count in the IL-2 group in most of the included trials (*high certainty evidence*). There was no statistically significant difference between viral load in both groups for measures less than 50 copies/mL or 500 copies/mL in most trials (*high certainty evidence*). IL-2 probably causes an increase in adverse effects, particularly grade 3 or 4 adverse effects (*moderate certainty evidence*). Most of the included trials reported similar adverse events, neutropenia, and myalgia were most commonly reported. There is probably no difference in the incidence of opportunistic infections in the IL-2 and control groups (*low certainty evidence*). Adherence was not reported in any of the included trials.

Overall completeness and applicability of evidence

We conducted a comprehensive search and included all relevant trials regardless of whether they reported the reviews outcomes of interest. Most included trials excluded participants who were

previously on immunomodulators or steroids, or with an autoimmune disease, or with malignancy requiring them to be on immunomodulators. The trials were conducted in different settings: including high- and middle-income countries. However, there is no plausible biological reason why the findings may not be applicable to low-income settings.

Quality of the evidence

We assessed the certainty of the evidence using the GRADE methodology, and presented the basis for the judgements in a 'Summary of findings' table. The overall certainty of evidence on the effects of IL-2 as an adjunct to ART for reducing morbidity and mortality in HIV-infected adults individuals can be described as high, which means that we are confident in this result and further research is unlikely to change the direction of the effect. This finding was consistent across all the included trials that reported on the outcome. In addition, IL-2 increases the CD4 cell count significantly and there is no difference in the proportion of participants with undetectable viral loads (*high certainty evidence*). IL-2 probably does not cause any important difference in the rates of opportunistic infections (*low certainty evidence*). However, it probably causes increased grade 3 or 4 adverse effects (*moderate certainty evidence*).

Potential biases in the review process

We conducted a comprehensive search to ensure that we identified all relevant completed or ongoing studies. There were no language or publication restrictions. We also reduced the potential bias in the conduct of this review: two review authors independently screened the search output, extracted data, and assessed the methodological certainty of each included trial.

Agreements and disagreements with other studies or reviews

The findings of this review are similar to those of a literature review by [Pett 2001](#), which showed that IL-2 adjunctive therapy can significantly increase the CD4 pool of HIV-positive participants compared to ART alone, however it has no significant effect on viral load, and has an increase in adverse effects, particularly grade 4 adverse effects in some trials and an acceptable adverse effect profile in others. [Pett 2010](#) concluded that IL-2 adjunctive therapy

confers no clinical benefit on HIV-positive participants and has no place in the therapeutic treatment of HIV. Three trials that we included in this Cochrane Review were also included in [Pett 2010](#) ([Abrams 2009a](#); [Abrams 2009b](#); [Stellbrink 2002](#)).

The findings of this Cochrane Review differ from those of a pooled meta-analysis of three randomized controlled trials (RCTs) by [Emery 2000](#), which showed a significant decrease in viral load in participants on IL-2 with ART compared to ART alone. However, [Emery 2000](#) also showed no significant increase in mortality and concluded that despite substantial improvement in CD4 cell count and viral load there was no significant improvement in clinical outcomes.

AUTHORS' CONCLUSIONS

Implications for practice

Interleukin-2 (IL-2) as an adjunct to ART leads to increases in CD4 cell counts in HIV-infected adults on ART. However, IL-2 (irrespective of the dose or duration) has no important effect on other clinically important positive outcomes, such as mortality, viral load reduction, and rates of opportunistic infections, but probably results in increased adverse effects. Our findings do not support the use of IL-2 as an adjunct to ART in HIV-infected adults.

Implications for research

Further RCTs on the use of IL-2 as adjunct to ART in HIV-infected adults are not justifiable based on the findings of this Cochrane review. However, further basic research may be helpful to explore why IL-2 causes increases in CD4 cell count.

ACKNOWLEDGEMENTS

We thank colleagues at Cochrane South Africa, South African Medical Research Council, Cape Town for technical and methodological support, particularly Joy Oliver for conducting the literature searches for this review. Tamara Kredo is partly supported by the Effective Health Care Research Consortium. This Consortium and the editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this publication do not necessarily reflect UK government policy.

REFERENCES

References to studies included in this review

Abrams 2002 *{published data only}*

Abrams DI, Bebhuk JD, Denning ET, Davey RT, Fox L, Lane HC, et al. Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm³: CPCRA 059. *Journal of Acquired Immune Deficiency Syndromes* 2002;**29**(3):221–31. PUBMED: 11873071]

Abrams 2009a *{published data only}*

Abrams D, Emery S, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. *Controlled Clinical Trials* 2002;**23**(2):198–220. PUBMED: 11943448]

Abrams 2009b *{published data only}*

INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, et al. Interleukin-2 therapy in patients with HIV infection. *New England Journal of Medicine* 2009;**361**(16):1548–59.

Amendola 2000 *{published data only}*

Amendola A, Poccia F, Martini F, Gioia C, Galati V, Pierdominici M, et al. Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group. *Clinical and Experimental Immunology* 2000;**120**(2):324–32. PUBMED: 10792383]

Caggiari 2001 *{published data only}*

Caggiari L, Zanussi S, Crepaldi C, Bortolin MT, Caffau C, D'Andrea M, et al. Different rates of CD41 and CD81 T-cell proliferation in interleukin-2-treated human immunodeficiency virus-positive subjects. *Cytometry (Communications in Clinical Cytometry)* 2001;**46**:233–7.

Carr 1998 *{published data only}*

Carr A, Emery S, Lloyd A, Hoy J, Garsia R, French M, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. *Journal of Infectious Diseases* 1998;**178**(4):992–9. PUBMED: 9806026]

Davey 2000 *{published data only}*

Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. *JAMA* 2000;**284**(2):183–9. PUBMED: 10889591]

de Boer 2003 *{published data only}*

de Boer AW, Markowitz N, Lane HC, Saravolatz LD, Koletar SL, Donabedian H, et al. A randomized controlled trial evaluating the efficacy and safety of intermittent 3-

, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100–300 CD4+ T cells. *Clinical Immunology* 2003;**106**(3):188–96. PUBMED: 12706405]

Dybul 2002 *{published data only}*

Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. *Journal of Infectious Diseases* 2002;**185**(1):61–8. PUBMED: 11756982]

Hengge 1998 *{published data only}*

Hengge UR, Goos M, Esser S, Exner V, Dötterer H, Wiehler H, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. *AIDS (London, England)* 1998;**12**(17):F225–34. PUBMED: 9863864]

Katlama 2002 *{published data only}*

Katlama C, Carcelain G, Duvalier C, Chouquet C, Tubiana R, De Sa M, et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082. *AIDS (London, England)* 2002;**16**(15):2027–34. PUBMED: 12370501]

Kelleher 1998 *{published data only}*

Kelleher AD, Roggensack M, Emery S, Carr A, French MA, Cooper DA. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. *Clinical and Experimental Immunology* 1998;**113**(1):85–91. PUBMED: 9697988]

Kovacs 1996 *{published data only}*

Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, Walker RE, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. *New England Journal of Medicine* 1996;**335**(18):1350–6. PUBMED: 8857018]

Lalezari 2000 *{published data only}*

Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, et al. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial. *HIV Clinical Trials* 2000;**1**(3):1–15. PUBMED: 11590500]

Levy 1999 *{published data only}*

Levy Y, Capitant C, Houhou S, Carriere I, Viard JP, Goujard C, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. *Lancet* 1999;**353**(9168):1923–9. PUBMED: 10371571]

Levy 2003 *{published data only}*

Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, et al. Effects of interleukin-2 therapy combined

with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. *AIDS (London, England)* 2003;**17**(3):343–51. PUBMED: 12556688]

Losso 2000 {published data only}

Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, et al. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts $\geq 350/\text{mm}^3$. *Journal of Infectious Diseases* 2000; **181**(5):1614–21. PUBMED: 10823761]

Marchetti 2002 {published data only}

Marchetti G, Meroni L, Varchetta S, Terzieva V, Bandera A, Manganaro D, et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. *Journal of Infectious Diseases* 2002;**186**(5):606–16. PUBMED: 12195347]

Marchetti 2004 {published data only}

Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, Galli M, et al. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. *AIDS (London, England)* 2004;**18**(2):211–6. PUBMED: 15075538]

Mitsuyasu 2007 {published data only}

Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial—AIDS Clinical Trials Group 328. *Archives of Internal Medicine* 2007;**167**(6):597–605. PUBMED: 17389292]

Ruxrungtham 2000 {published data only}

Ruxrungtham K, Suwanagoon S, Tavel JA, Chuenyam M, Kroon E, Ubolyam S, et al. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand. *AIDS (London, England)* 2000;**14**(16):2509–13. PUBMED: 11101062]

Stellbrink 2002 {published data only}

Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). *AIDS (London, England)* 2002;**16**(11):1479–87. PUBMED: 12131185]

Tambussi 2001 {published data only}

Tambussi G, Ghezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, et al. Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: a controlled study of 3 IL-2 regimens with antiviral drug therapy. *Journal of Infectious Diseases* 2001;**183**(10):1476–84.

Tavel 2003 {published data only}

Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, et al. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. *Journal of Infectious Diseases* 2003;**188**(4):531–6. PUBMED: 12898439]

Vogler 2004 {published data only}

Vogler MA, Tepler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, et al. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). *Journal of Acquired Immune Deficiency Syndromes* 2004;**36**(1):576–87. PUBMED: 15097300]

References to studies excluded from this review

Bosch 2010 {published data only}

Bosch RJ, Pollard RB, Landay A, Aga E, Fox L, Mitsuyasu R. Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328). *AIDS Research and Therapy* 2010;**7**:30.

Chun 1999 {published data only}

Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. *Nature Medicine* 1999;**5**(6):651–5. PUBMED: 10371503]

Crespo 2008 {published data only}

Crespo M, Caragol I, Falcó V, Ribera E, Urban S, Pahissa A. Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART. *Enfermedades Infecciosas y Microbiología Clínica* 2008;**26**(1):27–31.

Jacobson 2002 {published data only}

Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, et al. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. *AIDS (London, England)* 2002;**16**(8):1147–54. PUBMED: 12004273]

Kilby 2006 {published data only}

Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). *Journal of Infectious Diseases* 2006;**194**(12):1672–6. PUBMED: 17109338]

Lafeuillade 2001 {published data only}

Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Pisapia M, et al. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. *Journal of Acquired Immune Deficiency Syndromes* 2001;**26**(1):44–55. PUBMED: 11176268]

Martin 2005 *{published data only}*

Martin BK, Wu AW, Gelman R, Mitsuyasu RT, Adult AIDS Clinical Trials Group. Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous interleukin-2 administration. *Journal of Acquired Immune Deficiency Syndromes* 2005;**40**(4):428–33. PUBMED: 16280697]

Pett 2001 *{published data only}*

Pett SL, Emery S. Immunomodulators as adjunctive therapy for HIV-1 infection. *Journal of Clinical Virology* 2001;**22**(3):289–95. PUBMED: 11564594]

Tavel 2010 *{published data only}*

Tavel JA1, INSIGHT STALWART Study Group, Babiker A, Fox L, Gey D, Lopardo G, et al. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. *PLoS ONE* 2010;**5**(2):e9334.

Witzke 1998 *{published data only}*

Witzke O, Winterhagen T, Reinhardt W, Heemann U, Grosse-Wilde H, Kreuzfelder E, et al. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease. *Journal of Internal Medicine* 1998;**244**(3):235–40. PUBMED: 9747746]

Additional references**Abrams 2009**

INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, et al. Interleukin-2 therapy in patients with HIV infection. *New England Journal of Medicine* 2009;**361**(16):1548–59.

Blankson 2000

Blankson J, Siliciano RF. Interleukin 2 treatment for HIV infection. *JAMA* 2000;**284**(2):236–8. [DOI: 10.1001/jama.284.2.236

Castro 1992

Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *Morbidity and Mortality Weekly Report. Recommendations and Reports* 1992;**41**(RR-17):1–19.

Emery 2000

Emery S, Capra WB, Cooper DA, Mitsuyasu RT, Kovacs JA, Vig P, et al. Pooled analysis of 3 randomized controlled trials of interleukin 2 therapy in adult human immunodeficiency virus type 1 disease. *Journal of Infectious Diseases* 2000;**182**(2):428–34.

Grimwade 2009

Grimwade K, Swingler G. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. *Cochrane Database of Systematic Reviews* 2003, Issue 3. [DOI: 10.1002/14651858.CD003108

Guyatt 2008

Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE

evidence profiles and summary of findings tables. *Journal of Clinical Epidemiology* 2011;**64**(4):383–94.

Harari 2004

Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. *Blood* 2004;**103**(3):966–72. [DOI: 10.1182/blood-2003-04-1203

Higgins 2008a

Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester (UK): John Wiley & Sons, 2008.

Higgins 2008b

Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). *Cochrane Handbook for Systematic Reviews of Interventions*. Chichester (UK): John Wiley & Sons, 2008:187–241.

Horn 2002

Horn T. Proleukin (aldeseukin, Interleukin-2 or IL-2). www.aidsmed.com (accessed 23 August 2011).

Molina 2007

Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, et al. Abstract H-718: Intermittent interleukin-2 therapy to defer antiretroviral therapy in patients with human immunodeficiency virus infection. ICAAC. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sept 17–20; Chicago (IL). Chicago (IL), 2007.

Nachega 2011

Nachega J, Mugavero MJ, Zeier M, Vitória M, Gallant J. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. *Patient Preference and Adherence* 2011;**5**:357–67.

Pett 2010

Pett S, Kelleher AD, Emery S. Role of interleukin 2 in patients with HIV infection. *Drugs* 2010;**70**(9):1115–30.

Piliero 2003

Piliero PJ. Long-term toxicities associated with HIV and antiretroviral therapy. June 2003. <http://www.thebody.com/content/art12984.html> (accessed 26 December 2011).

Review Manager 5 [Computer program]

Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

UNAIDS 2016

UNAIDS. Global AIDS Update. 2016. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf. UNAIDS, (accessed 18 August 2016).

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Abrams 2002

Methods	Open-label randomized controlled trial (RCT)	
Participants	<p>Eligibility criteria</p> <ul style="list-style-type: none"> • HIV-positive. • Adults (18 years or older). • CD4 cell count of at least 300 cells/mm³. • Receiving or initiating combination antiretroviral therapy (ART) at the time of randomization. <p>Exclusion criteria</p> <ul style="list-style-type: none"> • Pregnancy. • AIDS-defining illness. • Malignancy requiring chemotherapy. • Use of systemic corticosteroid, hydroxyurea, or any other immunomodulator therapy within 4 weeks before randomization. • Autoimmune disease. • Breastfeeding. • Any central nervous system (CNS) abnormality requiring anti-seizure medication. <p>The trial included a total of 511 (256 in the interleukin group and 255 in the control group) HIV-1 infected adults</p> <ul style="list-style-type: none"> • Most participants were men (88.5%), white (69.3%), and had sex with a person of the same sex (76.7%). • Median CD4 cell count at randomization was 536 cells/mm³ (302 to 1591 cells/mm³). 	
Interventions	<p>Intervention group: intermittent administration of 2 doses (4.5 and 7.5 miu) of subcutaneous plus antiretroviral treatment (ART)</p> <p>Control group: ART alone.</p>	
Outcomes	<ul style="list-style-type: none"> • Viral load. • CD4 cell count. 	
Notes	<p>The trial was conducted in the USA.</p> <p>Duration of follow-up: minimum of 12 months. Median duration of follow-up was 16.2 months</p>	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The trial used permuted block randomization with stratification by the CPCRA unit

Abrams 2002 (Continued)

Allocation concealment (selection bias)	Low risk	The trial obtained random allocation of participants by calling the CPCRA Statistical Centre
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	Less than 15% of the participants were excluded from the final analysis or lost to follow-up, and it was by intention-to-treat (ITT) analysis
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	There was no evidence of bias from other sources.

Abrams 2009a

Methods	Open-label RCT	
Participants	Eligibility criteria: HIV-infected adult Exclusion criteria: not specified	
Interventions	Intervention group: 3 cycles and a dose of 7.5 miu of IL-2 twice daily plus ART Control group: ART alone .	
Outcomes	<ul style="list-style-type: none"> ● CD4 cell count. ● Viral load. ● Opportunistic infections. ● Death from any cause. ● Adverse events. 	
Notes	The trial was conducted in the USA. The median duration of follow-up was 7.0 years Ths trial was funded and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID)	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Abrams 2009a (Continued)

Random sequence generation (selection bias)	Low risk	The trial stratified randomization by individual clinical site
Allocation concealment (selection bias)	Low risk	The central coordinating facility prepared all randomizations schedules
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The analysis was based on an ITT principle and less than 15% were lost to follow-up
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	There was no evidence of other forms of bias.

Abrams 2009b

Methods	Open-label RCT
Participants	Eligibility criteria: HIV-positive adults with CD4 cell count between 50 and 299 cells/mm ³ Exclusion criteria: not specified
Interventions	Intervention group: 1 cycle of a dose of 4.5 miu twice daily for 5 consecutive days Control group: ART alone
Outcomes	<ul style="list-style-type: none"> ● CD4 cell count. ● Viral load. ● Opportunistic infections. ● Death from any cause. ● Adverse events.
Notes	The trial was conducted in the USA. The median duration of follow-up was 7.6 years The NIAID provided regulatory sponsorship, and Chiron, and subsequently Novartis

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The trial stratified randomization by individual clinical site

Abrams 2009b (Continued)

Allocation concealment (selection bias)	Low risk	The central co-ordinating facility prepares all randomization schedules
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The analysis was based on an ITT principle and less than 15% were lost to follow-up
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	There was no evidence of other forms of bias.

Amendola 2000

Methods	Open-label RCT
Participants	<p>22 HIV-infected adults (12 males and 10 females)</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> ● HIV-infected adults > 18 years of age. ● Asymptomatic. ● CD4 cell count > 400 to 600 cells/mm³. ● Viral load > 5000 copies/mL. <p>Exclusion criteria</p> <ul style="list-style-type: none"> ● Prior exposure to antiretrovirals, immunomodulators, corticosteroids. ● Hepatitis B and C infection. ● Patients with autoimmune disease.
Interventions	<p>The participants were enrolled in 3 randomized groups.</p> <ul style="list-style-type: none"> ● Six participants (group 1) were treated with ART (Indinavir 2400 mg/day; stavudine 60 ± 80 mg/day; lamivudine 300 mg/day). ● Eight participants (group 2) were treated with ART and IL-2 (aldesleukin, 1000 000 U/day) subcutaneously, 5 days/week at alternative weeks). ● Eight participants (group 3) received granulocyte colony-stimulating factor (G-CSF; filgrastim, 5 mg/kg per day, for 5 consecutive days) to stimulate hematopoietic progenitor cell mobilization before starting ART and rIL-2. <p>All participants were treated with ART for 1 month before receiving differentiated therapies (ART; ART 1rIL-2; (G-CSF) ART 1rIL-2) for an additional 12/24 weeks</p>
Outcomes	<ul style="list-style-type: none"> ● CD4 cell count. ● Viral load. ● Level of peripheral mononuclear blood cell apoptosis. ● Expression of CD45RA and CD62L T naive cells and memory cells.

Amendola 2000 (Continued)

Notes	The trial was conducted in Italy. Duration of follow-up: 24 weeks. Outcomes were analysed at baseline, 12, and 24 weeks.	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not describe whether this was done or not
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe whether this was done or not
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The study was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	We do not have enough information from the trial to make a judgement
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	We did not identify any other potential sources of bias.

Caggiari 2001

Methods	Paralell single centred RCT
Participants	14 HIV-infected adults Inclusion criteria <ul style="list-style-type: none"> • ART naive. • CD4 > 200 cells/mm³. • HIV viraemia > 500 copies/mL. • No previous IL-2 therapy. • At least 18 years of age. • 1000 granulocytes/mm³. Exclusion criteria <ul style="list-style-type: none"> • Abnormal thyroid function and cardiovascular. • Abnormal pulmonary and central nervous system involvement.
Interventions	Intervention group: 6 miu of IL-2 from days 1 to 5 and 8 to 12 of a 28 day cycle for 6 cycles plus ART(2 reverse transcriptase inhibitors and indinavir) Control group: ART alone

Caggiari 2001 (Continued)

Outcomes	<ul style="list-style-type: none"> • CD4 cell count. • Viral load. 	
Notes	This trial was conducted in Italy. Duration of follow-up: 12 months.	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	There was no mention of the specific method of sequence generation or randomization but in the discussion section it was stated that randomization was done to ensure comparability of both groups
Allocation concealment (selection bias)	Unclear risk	There was no mention of the specific method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and not likely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	We do not have enough information from the study to make a judgement
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	We did not identify any other potential sources of bias.

Carr 1998

Methods	RCT
Participants	<p>115 HIV-infected adults</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • HIV-infected adults > 18 years of age. • CD4 lymphocyte count between 200 and 500 cells/mm³. • Karnofsky score = 60. • At least 2 months of continuous antiretroviral therapy (ART) at study initiation. • No prior IL-2 therapy. • No AIDS-defining illness. <p>Exclusion criteria: not specified</p>

Interventions	<p>There were 3 trial arms</p> <ul style="list-style-type: none"> • Intravenous IL-2 plus ART, 12,000,000 IU of IL-2 daily for 5 days every eight weeks (27 participants). • Subcutaneous PEG IL-2 plus ART, 1,000,000 IU per cycle in equal divided doses in day 1 and 3 every eight weeks (58 participants). • ART alone (30 participants). <p>ART consisted of zidovudine + didanosine + zalcitabine</p>	
Outcomes	<ul style="list-style-type: none"> • CD4 cell count. • CD8 cell count. • Adverse events. 	
Notes	<p>The trial was conducted in Australia. Duration of follow-up: 12 months</p>	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial not describe the method for sequence generation.
Allocation concealment (selection bias)	Unclear risk	The trial did not described the method for allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial authors analysed all participants included in the trial
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	High risk	There was a high risk of selection bias and detection bias. Participants were randomized on a 1:2:1 basis for the continuous intravenous IL-2, PEG-IL-2 (Polyethylene glycol) modified IL-2, and control groups respectively. The trial authors rationalized that the unequal randomization allowed for determination of the maximally tolerated dose significance levels of PEG IL-2 as well as its efficacy. This was bound to cause selection bias. Secondly, IL-2 participants were hospitalized the first 5 to 6 days of the cycle causing possible detection bias

Davey 2000

Methods	Multicentred RCT
Participants	Inclusion criteria: HIV-infected adults Exclusion criteria: not specified
Interventions	Intervention: 6 cycles of IL-2, 7.5 miu + ART Control: ART alone
Outcomes	CD4 cell count Viral load Adverse events
Notes	The trial was conducted in the USA. Duration of follow-up was 12 months

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The trial randomly assigned participants to treatment groups by a computer generated block randomization with block sizes of 4 for the first 2 blocks and subsequently block sizes of 2
Allocation concealment (selection bias)	Low risk	Central randomization by a biostatistician who was not part of the data analysis
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Biostatisticians were blinded from knowing which participants were in which treatment groups
Incomplete outcome data (attrition bias) All outcomes	Low risk	It is unlikely that there was attrition bias since < 15% withdrew or were lost to follow-up. There was no differential loss to follow-up
Selective reporting (reporting bias)	Low risk	There was no evidence of selective outcome reporting.
Other bias	Low risk	There was no evidence of other potential sources of bias.

de Boer 2003

Methods	Multi-centred RCT
Participants	<p>Inclusion criteria</p> <ul style="list-style-type: none"> • Karnofsky performance score greater than or equal to 70. • HIV-positive participant aged 18 years and above. • CD4 cell counts of between 100 to 300 cells/mm³. • Prior use of stable ART regimen for at least 2 months before the trial. • No AIDS defining illness except kaposi's Sarcoma or pneumocystis jirovecii pneumonia. <p>Exclusion criteria: not specified</p>
Interventions	<p>Treatment group: participants received intravenous recombinant IL-2 12 miu/day for 3, 4, or 5 days + ART every 8 weeks for 6 cycles</p> <p>Control group: ART alone</p>
Outcomes	<ul style="list-style-type: none"> • Change in CD4 cell count. • Viral load. • Adverse effects. • AIDS defining illness.
Notes	The trial was conducted in USA. Duration of follow-up was 12 months

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	There is likely to be a low risk of selection bias as participants were assigned in equal proportions of 1 to 4 treatments and participants were stratified by treatment centre
Allocation concealment (selection bias)	Low risk	Randomization was done centrally.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial addressed loss to follow-up and was less than 15%.
Selective reporting (reporting bias)	Low risk	There was no evidence of potential reporting bias from selective reporting
Other bias	Low risk	There was no evidence of other potential sources of bias.

Dybul 2002

Methods	RCT
Participants	<p>9 participants</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • HIV RNA level of > 500 copies/mL. • Documented HIV infection of < 6 months with participant already on ART. • Non-reactive ELISA within 6 months of enrolment. • participants with a history of symptoms or prior exposure to acute antiretroviral syndrome and a non reactive western blot within 6 months of enrolment. • participants with a history of symptoms or prior exposure to acute antiretroviral syndrome and an indeterminate western blot within 6 months of enrolment. <p>Exclusion criteria: not specified</p>
Interventions	<p>Treatment group: intermittent IL-2 administered subcutaneously in 3 cycles for 5 days every 8 week plus ART</p> <p>Control group: ART alone. regimen: stavudine 30 mg to 40 mg twice daily, lamivudine 150 mg twice daily, indinavir 800 mg twice daily</p>
Outcomes	<ul style="list-style-type: none"> • CD4 cell count. • Lymphocyte subsets including CD4+, CD45RO, CD3+, CD8+.
Notes	This was a pilot study conducted in the USA. Duration of follow-up: 12 months

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not provide any details.
Allocation concealment (selection bias)	Unclear risk	The trial authors did not provide any details.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	We do not have enough information from the trial to make a judgement
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	We did not identify any other potential sources of bias.

Hengge 1998

Methods	This was a prospective RCT
Participants	There was a total of 64 participants. Inclusion criteria <ul style="list-style-type: none"> • Adult HIV-positive participants with CD4 count between 200 to 500 cells/mm³. • Normal haematological, hepatic, biliary, and renal function. • Had been receiving stable ART (saquinavir, lamivudine, and zidovudine) Exclusion criteria: not specified
Interventions	Treatment group A (22): ART plus subcutaneous IL-2 administered at a dose of 9.6 miu daily in cycles consisting of 5 days. A total of 5 cycles were given. One cycle was given every 6 weeks over a period of 52 weeks Treatment group B (22): ART plus subcutaneous IL-2 administered at a dose of 9.6 miu daily whenever CD4 counts dropped to below 1.25 fold of individual's baseline value Control group: ART alone participants were followed up for a duration of 12 months
Outcomes	<ul style="list-style-type: none"> • Change in CD4 count. • Proportion of people with undetectable viral load. • Opportunistic infections. • Adverse effects
Notes	The trial was conducted in Germany. Duration of follow-up: 12 months

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	There was no true randomization as controls were chosen from participants fulfilling the inclusion criteria who did not wish to experience the potentially adverse effects of IL-2 Secondly, the trial authors did not describe the method of sequence generation
Allocation concealment (selection bias)	High risk	There is unlikely to be allocation concealment based on the support for judgement for sequence generation above
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	There is unlikely to have been attrition bias as the trial excluded less than 15% of the participants

Hengge 1998 (Continued)

Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting of outcomes.
Other bias	Low risk	There were no other potential sources of bias.

Katlama 2002

Methods	Multicentred open label RCT
Participants	A total of 72 participants. Inclusion criteria <ul style="list-style-type: none"> • 18 years or older. • CD4 cells counts 25-200 cells/mm³. • Viral load of < 1000 copies/mL while receiving ART (2 nucleoside analogues and 1 protease inhibitor (PI)) for 3 months. Exclusion criteria: participants on cytotoxic chemotherapy or corticosteroids within 3 months prior to the trial
Interventions	Intervention: 4.5 miu of IL-2 administered subcutaneously plus ART every 6 weeks for 4 cycles, every 12 hours for 5 days Control: ART alone
Outcomes	<ul style="list-style-type: none"> • Plasma HIV RNA levels. • CD4 and CD8 count.
Notes	The trial was conducted in 18 clinical centres in France. Duration of follow-up: 24 weeks.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The trial performed randomization of participants by using computer-generated random numbers
Allocation concealment (selection bias)	Low risk	The trial performed allocation centrally.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial authors used ITT for the primary outcome.

Katlama 2002 (Continued)

Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	We did not identify any other potential sources of bias.

Kelleher 1998

Methods	This was a single centred pilot study which was planned as a pilot study of a multi-centred RCT to be conducted	
Participants	<p>18 participants consecutively enrolled into 3 groups</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • Adults who had asymptomatic HIV infections. • CD4 counts between 200 to 500 cells/mm³. • Receiving nucleoside analogue ART regimen. <p>Exclusion criteria: not specified</p>	
Interventions	<p>Treatment group A (IL-2 plus ART only)</p> <ul style="list-style-type: none"> • IL-2 at doses of 12.6 X 10⁶ U/day <p>as continuous intravenous infusions for 5 days every 8 weeks for 6 cycles</p> <p>Treatment group B (IL-2 linked to polyethylene glycol plus ART)</p> <ul style="list-style-type: none"> • Escalating doses of subcutaneous injections of IL- 2 on day 1 and 3 of each 8-week cycle. <p>Control group</p> <ul style="list-style-type: none"> • ART alone. <p>Each group had 150 mg of lamivudine twice daily added to their regimen at 30 weeks</p>	
Outcomes	<ul style="list-style-type: none"> • CD4 cell counts. • Viral loads. • Responses to recall antigens. 	
Notes	<p>This was a multicentred trial conducted in Australia.</p> <p>Duration of follow-up: 48 weeks</p>	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not describe the method of random sequence generation
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding

Kelleher 1998 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial excluded less than 15% of the participants.
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	We did not identify any other potential sources of bias.

Kovacs 1996

Methods	This was a single-centred RCT
Participants	A total of 60 participants were randomized Inclusion criteria <ul style="list-style-type: none"> • HIV-positive participants aged 18 years and older. • No history of opportunistic infection. • CD4 counts > 200 cells/mm³. • Not received corticosteroids or cytotoxic chemotherapy. • participants who had not received any experimental therapy in the preceding 4 weeks. Exclusion criteria: not specified
Interventions	Treatment group: intravenous IL-2 given at intermittent infusions of 18 miu plus ART Control group: ART alone consisting of zidovudine, zalcitabine, or stavudine with didanosine
Outcomes	<ul style="list-style-type: none"> • Viral load. • CD4 cell count.
Notes	Study was conducted in the USA. The duration of follow-up was 14 months.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not describe the method of sequence generation
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment

Kovacs 1996 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	Less than 15% were lost to follow-up and the trial authors described withdrawals
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	We did not identify any other potential sources of bias.

Lalezari 2000

Methods	Multicentred phase 2 RCT
Participants	A total of 115 participants Inclusion criteria <ul style="list-style-type: none"> • HIV-infected individuals on ART (highly active antiretroviral therapy) • CD4 cell count < 300 cells/mm³. • Viral load < 500 copies/mL. • ART experienced. Exclusion criteria: not specified
Interventions	Treatment group (IL-2 plus ART): 51 participants <ul style="list-style-type: none"> • Low dose IL-2 administered subcutaneously at 1.2 miu once daily for 6 months Control group: ART alone <ul style="list-style-type: none"> • participants continued on their current regimen and received HAART alone
Outcomes	<ul style="list-style-type: none"> • CD4 cell counts. • Adverse effects. • Viral load.
Notes	This trial was conducted in the USA. Duration of follow-up: 26 weeks

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Sequence generation was by block randomization stratified by study site
Allocation concealment (selection bias)	Low risk	The trial authors used a central randomization process.

Lalezari 2000 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcomes measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	More than 15% withdrew from the trial due to adverse effects and the trial authors did not analyse their results
Selective reporting (reporting bias)	Low risk	There was no evidence of selective outcome reporting.
Other bias	Low risk	There was no evidence of any other sources of bias.

Levy 1999

Methods	Multicentred an open label RCT
Participants	A total of 94 participants Inclusion criteria <ul style="list-style-type: none"> • Participants aged 18 years and above. • With asymptomatic HIV infection. • ART naive. • Also naive to corticosteroids, chemotherapy, and experimental therapy. • CD4 counts between 250 to 550 cells/mm³. Exclusion criteria: not specified
Interventions	<ul style="list-style-type: none"> • Polyethylene-glycol (PEG) modified IL-2 administered as 2 miu intravenous bolus for 7 cycles from 2nd week to 50th week plus ART • Control group: ART alone.
Outcomes	<ul style="list-style-type: none"> • Proportion of people with 80% rise in CD4 count. • Change in CD4 cell count. • Viral load change from baseline to end of study. • Adverse effects.
Notes	This study was conducted in 14 university clinics in France.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not describe the method of random sequence generation

Levy 1999 (Continued)

Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	There was no evidence of incomplete outcome data. Less than 15% were lost to follow-up
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting bias.
Other bias	Low risk	There was no evidence of other sources of bias.

Levy 2003

Methods	This was a prospective RCT.
Participants	<p>There were a total of 118 participants</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> Asymptomatic HIV participants who were either completely ART naive or naive to PIs alone. Were over 18 years of age. Had a CD4 cell count of between 200 to 550 cells/mm³. <p>Exclusion criteria: not specified</p>
Interventions	<p>Treatment group: ART started 4 weeks before plus subcutaneous IL-2 administered at a dose of 5 miu twice daily for 5 days given every 4 weeks for the first 3 cycles and then subsequently every 8 weeks for the next 7 cycles</p> <p>Control group: ART alone consisting of lamivudine (300 mg/day), stavudine (60 to 80mg/day), and indinavir (2400 mg/day)</p>
Outcomes	<ul style="list-style-type: none"> Absolute and percentage change in CD4 cell counts. Proportion of participants with at least a 50% rise in CD4 cell counts at weeks 72 to 74 from baseline. Viral load. AIDS defining events. Adverse effects. Adherence.
Notes	<p>This was a multicentred study conducted in 14 university clinics in France</p> <p>Duration of follow-up was 18 months.</p>

Levy 2003 (Continued)

<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The trial authors did not describe the method of sequence generation. However, the trial authors mentioned that randomization was centralized and stratified according to ART status
Allocation concealment (selection bias)	Low risk	The trial authors used a centralized method of randomization
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial excluded less than 15% (2 out of 118 participants) from the analysis. There was no differential loss to follow-up
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	There was no evidence of other sources of bias.

Losso 2000

Methods	Study design was a prospective open-labelled RCT
Participants	<p>There were a total of 73 participants</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • HIV participants who had been on ART For greater than or equal to 7 days. • Not pregnant with a Karnofsky performance score ≥ 80. • Were over 18 years of age. • Had a most recent CD4 cel count of > 350 cells/mm³. <p>Exclusion criteria</p> <ul style="list-style-type: none"> • History of or presence of AIDS defining illness. • History of malignancy requiring systemic use of corticosteroids or immuno modulators within the prior 5 years. • Autoimmune/inflammatory disease like Crohns disease.
Interventions	<ul style="list-style-type: none"> • Treatment group: subcutaneous IL-2 given at escalating doses of 1.5 miu, 4.5 miu, 7.5 miu with ART given twice daily for 5 consecutive days every 8 weeks plus ART. • Control group: ART alone.

Losso 2000 (Continued)

Outcomes	<ul style="list-style-type: none"> • Proportion of participants with viral load \leq 500 copies/mL. • Mean change in CD4 cell count. • Mean change in viral load. 	
Notes	This was a multi-centred trial conducted in 6 clinical centres in Buenos Aires, Argentina	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The trial used a stratified block randomization method, using blocks of 24 stratified according to ART history (naive or experienced) and clinical centres
Allocation concealment (selection bias)	Low risk	The trial used a centralized method of randomization.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial excluded less than 15% (2 out of 73 participants) from the analysis. There was no differential loss to follow-up
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	High risk	There was more monitoring in the treatment group compared to the control group

Marchetti 2002

Methods	Open labelled parallel RCT
Participants	<p>22 participants were randomized:</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • 18 years and above. • Immunological non-responders (INRs), that is participants on ART showing failure to restore their circulating CD4 counts despite good control of HIV plasma

	<p>viraemia and have received an ART regimen consisting of 2 nucleoside reverse transcriptase inhibitors (NRTI) and 1 PI for at least a year.</p> <ul style="list-style-type: none"> • Have HIV RNA load of < 50 copies/mL for at least 6 months. <p>Exclusion criteria</p> <ul style="list-style-type: none"> • Pregnant women. • Active drug users (alcohol abusers). • participants with cardiovascular and thyroid disorders. • Previously treated with cytotoxic drugs or growth factors. • participants who were previously not compliant with ART medication.
Interventions	<p>Treatment group (12): they were commenced on IL-2 for a 4 week cycle for 3 cycles plus ART</p> <p>Control group (10): ART consisting of 2 nucleoside reverse transcriptase inhibitors (NRTI) and 1 PI</p>
Outcomes	<ul style="list-style-type: none"> • Proportion of participants with undetectable viral load. • Mean change in CD4 count. • Change in CD8 count. • Opportunistic infections. • Adverse events.
Notes	This trial was an explanatory trial conducted at the University of Milan, Italy

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not describe the method of sequence generation
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial followed up all participants to the end of the trial, and even included those who were lost to follow-up afterwards in the results
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting bias.
Other bias	Low risk	There was no evidence of other potential sources bias.

Methods	This was a RCT
Participants	<p>There were a total of 15 participants</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • Participants on ART showing failure to restore their circulating CD4 counts despite good control of HIV plasma viraemia and have received ART regimen consisting of 2 nucleoside reverse transcriptase inhibitors (NRTI) and 1 PI for at least a year. • CD4 cell counts constantly less than or equal to 200 cells/mm³ and HIV RNA load of < 50 copies/mL after 12 months of stable ART. <p>Exclusion criteria</p> <ul style="list-style-type: none"> • Not specified.
Interventions	<p>Treatment group (8): participants received 3 cycles of low dose subcutaneous IL-2 over a 48-week period. Each cycle consisted of 3 miu IL-2 administered at days of 1 to 5 and days 8 to 12 of a 10-week duration plus ART</p> <p>Control group (7): ART alone</p>
Outcomes	<ul style="list-style-type: none"> • Percentage change in CD4 count. • Absolute change in CD4 count.
Notes	This was a small immunological trial conducted to investigate the long-term kinetics of CD4 and CD8 cells when low dose IL-2 is administered in Milan, Italy

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not describe the method of sequence generation
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	There was no loss to follow-up.
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting of outcomes.
Other bias	Low risk	We did not identify any other potential sources of bias.

Methods	This was a multi-arm parallel RCT
Participants	<p>There were a total of 159 participants</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • HIV-positive participants without AIDS defining illness. • ART naive or had been treated only reverse transcriptase inhibitors (RTI) and 1 PI for at least a year. • CD4 cell counts constantly from 50 to 350 cells/mm³ and HIV RNA load of < 50 copies/mL after 12 months of stable ART. <p>Exclusion criteria</p> <ul style="list-style-type: none"> • Previous use of PIs or IL-2 therapy. • Cardiac disease.
Interventions	<p>Treatment group A (intravenous IL-2 plus ART): received continuous infusions of IL-2 at doses of 9 miu for 5 days every 8 weeks plus ART</p> <p>Treatment group B (subcutaneous IL-2 plus ART): received subcutaneous injections of IL-2 7.5 miu twice daily for 5 days every 8 weeks plus ART</p> <p>Control group: ART alone, 2 NRTIs, and a PI</p>
Outcomes	<ul style="list-style-type: none"> • Change in CD4 count • Change in plasma viral levels. • Adverse effects. • All-cause mortality.
Notes	<p>This was a multicentred trial conducted at 26 AIDS Clinical Trials Group (ACTG) sites in the USA</p> <p>Duration of the trial was 84 weeks.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	There is likely to be a low risk of selection bias because although the trial authors did not describe the method of sequence generation, participants were randomized in proportions of 1:1:1 and stratified by participation in a previous trial ACTG 928 and nucleosides
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding

Mitsuyasu 2007 (Continued)

Incomplete outcome data (attrition bias) All outcomes	High risk	The trial excluded more than 15% of participants from the analysis
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	There was no evidence of other potential sources of bias.

Ruxrungtham 2000

Methods	Multicentred parallel RCT
Participants	Inclusion criteria <ul style="list-style-type: none"> • HIV-infected adults. Exclusion criteria <ul style="list-style-type: none"> • History of AIDS defining illness, malignancy needing treatment within the last 5 years, medical condition corticosteroids, or cytotoxic chemotherapy.
Interventions	Treatment groups (A, B, and C): received 1.5 miu, 4.5 miu, and 7.5 miu of IL-2 administered twice daily for 5 days, every 8 weeks for three cycles Control groups: ART alone.
Outcomes	<ul style="list-style-type: none"> • Change in CD4 count. • Change in viral load. • Proportion of undetectable viral load.
Notes	This was a multi-arm pragmatic trial conducted in Thailand. Duration of follow-up was 24 weeks.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The trial authors did not clearly specify the method of random sequence generation but it appeared to be low risk. Randomization was stratified by clinical centre and ART treatment history, that is naive or pretreated
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding

Ruxrungtham 2000 (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	The trial authors did not describe withdrawals or missing data
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	There was no evidence of other potential sources of bias.

Stellbrink 2002

Methods	Prospective RCT
Participants	<p>There were 56 participants.</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • Asymptomatic HIV participants. • Had a CD4 cel count of > 350 cells/mm³. • plasma viral load > 400 copies/mL. • Had seroconverted 12 months prior to entry. • Aged between 18 to 70 years. <p>Exclusion criteria</p> <ul style="list-style-type: none"> • History of AIDS defining illness (Castro 1992). • Malignancy needing treatment within the last 5 years. • Medical condition corticosteroids.
Interventions	<ul style="list-style-type: none"> • Treatment group (27): ART plus recombinant subcutaneous IL-2 at 9 MU (megaunits) once daily (with an option to switch to 4.5 MU twice daily) for 5 consecutive day • Control group (29): ART alone consisting of stavudine 30 to 40 mg twice daily, and lamivudine 150 mg twice daily, nelfinavir 750 mg 3 times daily, and saquinavir 600 mg 3 times daily.
Outcomes	<ul style="list-style-type: none"> • Change in CD4 count • Change in plasma viral levels
Notes	This was an open label RCT conducted in Germany. Mean follow-up duration ranged from 582 - 601 days

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not report the method of sequence generation

Stellbrink 2002 (Continued)

Allocation concealment (selection bias)	Unclear risk	The trial authors did not report the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial authors performed analysis was ITT and there were no losses to follow-up
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	There was no evidence of other potential sources of bias.

Tambussi 2001

Methods	This was a phase 2 RCT.	
Participants	<p>There was a total of 61 participants.</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • HIV-infected adults with CD4 cell count of between 200 to 550 cells/mm³, plasma viral load > 400 copies/mL. <p>Exclusion criteria: not specified</p>	
Interventions	<p>Treatment arm A (high dose intravenous arm): ART plus 12 miu of IL-2 by continuous intravenous infusion followed by subcutaneous 7.5 miu IL-2 twice a day for 5 days every 8 weeks for the remaining 4 cycles</p> <p>Treatment arm B (high dose subcutaneous arm): ART+subcutaneous 7.5 miu IL-2 twice a day for 5 days every 8 weeks for 6 cycles</p> <p>Treatment arm C (low dose arm): ART plus subcutaneous IL-2 +3 miu twice a day every 4 weeks</p> <p>Control: ART alone</p>	
Outcomes	<ul style="list-style-type: none"> • Change in CD4 count. • Change in plasma viral levels. • Adverse effects. 	
Notes	This was an phase 2 RCT conducted in Milan Italy. The duration of follow-up was a 12 months	
Risk of bias		
Bias	Authors' judgement	Support for judgement

Tambussi 2001 (Continued)

Random sequence generation (selection bias)	Unclear risk	The trial authors did not report the method of sequence generation
Allocation concealment (selection bias)	Unclear risk	The trial authors did not report the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial authors performed analysis by ITT principle and less than 15% of participants were lost to follow-up
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	High risk	There were differential treatment participants in the 2 groups. Participants were followed up as outpatients in 1 group and as inpatients in the other group

Tavel 2003

Methods	This was a double blinded randomized placebo controlled trial
Participants	<p>There were a total of 19 participants.</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> • HIV-positive participants with a CD4 cell count ≥ 350 cells/mm³ ≤ 1 month before the trial. • Had been stable on 2 nucleosides analogue reverse transcriptase inhibitor and either a non-nucleoside analogue reverse transcriptase inhibitor or PI. <p>Exclusion criteria</p> <ul style="list-style-type: none"> • History of AIDS defining illness. • Malignancy requiring treatment during the preceding 5 years. • Medical conditions requiring cytotoxic chemotherapy.
Interventions	<p>Group A: subcutaneous IL-2 (7.5 miu IL-2 twice daily for 5 days) and placebo) plus ART</p> <p>Group B: IL-2 (7.5 miu IL-2 twice daily for 5 days) and 0.5 mg prednisone/kg/day for 7 days every 8 weeks plus ART</p> <p>Group C: 0.5 mg prednisone/ kg/day for 7 days every 8 weeks plus ART</p> <p>Group D: placebo orally for 7 days (1 cycle) every 8 weeks plus ART</p>
Outcomes	<ul style="list-style-type: none"> • Viral load • Change in CD4 cell count.

Tavel 2003 (Continued)

Notes	This study was conducted in the USA. Duration of follow-up was 12 months	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not describe the method of sequence generation
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	There was no loss to follow-up and ITT.
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	There was no evidence of other potential sources of bias.

Vogler 2004

Methods	This was a phase 2 multi-centred randomized open label trial
Participants	<p>There was a total of 115 participants</p> <p>Inclusion criteria</p> <ul style="list-style-type: none"> ● HIV-infected participants confirmed by serology, > 18 years old. ● CD4 cell count of between 300 to 700 cells/mm³. ● Stable on single or dual nucleoside therapy for at least 2 months. ● No history of AIDS defining illness (Castro 1992) ● No IL-2 treatment within the last 3 months. <p>Exclusion criteria</p> <ul style="list-style-type: none"> ● History of AIDS defining illness. ● Systemic malignancies, or cardiac disease, or untreated thyroid disease. ● Pregnant and breast feeding women, as well as asthmatic and autoimmune disease participants.

	<ul style="list-style-type: none"> • Active opportunistic infection. • No immunomodulating drugs, or cytotoxic chemotherapy, or systemic corticosteroids at least 4 weeks before trial.
Interventions	Treatment group: self administered subcutaneous IL-2 1 miu daily in 0.2 mL volume at rotating skin sites in combination with continued ART Control: ART alone.
Outcomes	<ul style="list-style-type: none"> • Viral load. • Change in CD4 cell count. • Adverse effects. • Adherence. • All-cause mortality.
Notes	This trial was conducted in the USA. The duration of follow-up was 24 weeks.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not describe the method of sequence generation
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe the method of allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	The trial was not blinded. However, the outcome measures are objective and unlikely to have been influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	The trial excluded less than 15% from the analysis.
Selective reporting (reporting bias)	Low risk	There was no evidence of selective reporting.
Other bias	Low risk	There was no evidence of other potential sources of bias.

Abbreviations: AIDS: acquired immunodeficiency virus; ART: antiretroviral therapy; CNS: central nervous system; PEG: polyethylene glycol; HIV: human immunodeficiency virus; ITT: intention to treat; IL-2: interleukin-2; NRTI: nucleoside reverse transcriptase inhibitors; PI: protease inhibitor; RCT: randomized controlled trial; USA: United States of America.

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Bosch 2010	Both the intervention and control group received interleukin-2 (IL-2)
Chun 1999	This was a cross-sectional study
Crespo 2008	This was a cohort study
Jacobson 2002	This was a study of interleukin-12 (IL-12) and not IL-2
Kilby 2006	Participants in the intervention group received both IL-2 and a vaccine
Lafeuillade 2001	Participants in the intervention group received both IL-2 and interferon-gamma
Martin 2005	The study did not report any outcomes relevant to this review
Pett 2001	This was a review of randomized controlled trials
Tavel 2010	The study compared participants receiving no treatment, IL-2 alone, or IL-2 with antiretroviral treatment (ART)
Witzke 1998	Here the comparison was between subcutaneous IL-2 and ART and intravenous IL-2 and ART. The control group was not relevant to this review

Abbreviations: IL-2: interleukin-2.

DATA AND ANALYSES

Comparison 1. Interleukin-2 versus control


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All-cause mortality	6	6565	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.80, 1.17]
1.1 ART experienced	2	626	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.16, 7.11]
1.2 ART naive or not specified	4	5939	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.80, 1.17]
2 HIV RNA levels < 50 cells/mL	5	805	Risk Ratio (M-H, Random, 95% CI)	0.97 [0.81, 1.15]
3 HIV RNA levels < 500 cells/mL	4	5929	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.82, 1.12]
4 Opportunistic infections	7	6141	Risk Ratio (M-H, Random, 95% CI)	0.79 [0.55, 1.13]
4.1 ART experienced	2	97	Risk Ratio (M-H, Random, 95% CI)	0.30 [0.05, 1.86]
4.2 ART naive or not specified	5	6044	Risk Ratio (M-H, Random, 95% CI)	0.81 [0.56, 1.19]
5 Adverse events (grade 3 or 4)	6	6291	Risk Ratio (M-H, Random, 95% CI)	1.47 [1.10, 1.96]

Analysis 1.1. Comparison 1 Interleukin-2 versus control, Outcome 1 All-cause mortality.


Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults

Comparison: 1 Interleukin-2 versus control

Outcome: 1 All-cause mortality



(... Continued)




Analysis 1.2. Comparison 1 Interleukin-2 versus control, Outcome 2 HIV RNA levels < 50 cells/mL.

Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults

Comparison: 1 Interleukin-2 versus control

Outcome: 2 HIV RNA levels < 50 cells/mL




Analysis 1.3. Comparison 1 Interleukin-2 versus control, Outcome 3 HIV RNA levels < 500 cells/mL.

Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults

Comparison: 1 Interleukin-2 versus control

Outcome: 3 HIV RNA levels < 500 cells/mL




Analysis 1.4. Comparison 1 Interleukin-2 versus control, Outcome 4 Opportunistic infections.

Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults

Comparison: 1 Interleukin-2 versus control

Outcome: 4 Opportunistic infections




Analysis 1.5. Comparison 1 Interleukin-2 versus control, Outcome 5 Adverse events (grade 3 or 4).

Review: Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults

Comparison: 1 Interleukin-2 versus control

Outcome: 5 Adverse events (grade 3 or 4)



ADDITIONAL TABLES

Table 1. Details of the interleukin-2 intervention regimen

Number	Trial ID	Follow-up duration	Dosing regimen for interleukin-2 (IL-2)	Comparisons	Outcomes	ART experienced or naive
1	Abrams 2002	16 months	Dose: 2 doses (4.5 and 7.5 miu) Route: subcutaneous Duration: twice daily for 5 days every 8 weeks	ART not specified	Viral load CD4 cell count	ART experienced

Table 1. Details of the interleukin-2 intervention regimen (Continued)

2	Abrams 2009b	7 years	Dose: 4.5 miu Route: subcutaneous Duration: twice daily, 6 cycles	ART not specified	Opportunistic infections Death from any cause Adverse events	Not specified
3	Abrams 2009a	7 years	Dose: 7.5 miu Route: subcutaneous Duration: twice daily, 3 cycles	ART not specified	Opportunistic infections Death from any cause Adverse events	Not specified
4	Amendola 2000	28 weeks	Dose: 1 miu Route: subcutaneous Duration: daily for 5 days/week every alternate week for 3 months	Indinavir, stavudine, and lamivudine	CD4 cell count Viral load	ART naive
5	de Boer 2003	12 months	Dose: 12 miu Route: intravenous Duration: for 3, 4, or 5 days every 8 weeks for 6 cycles	ART not specified	CD4 cell count Viral load Adverse events and serious adverse events AIDS defining complex	ART experienced
6	Caggiari 2001	12 months	Dose: 6 miu Route: subcutaneous Duration: from days 1 to 5 and days 8 to 12 of a 28-day cycle for 6 cycles	2 nucleoside reverse transcriptase inhibitors (NRTIs) or 2 NRTIs and indinavir	CD4 cell count Viral load	ART naive
7	Carr 1998	12 months	Dose: 1 miu Route: subcutaneous and intravenous Duration: Group A: 12 miu daily for 5 days every 8 weeks (27 participants) Group B: 1 miu	Zidovudine + didanosine + zalcitabine	CD4 cell count Adverse events Viral load Opportunistic infections	ART experienced

Table 1. Details of the interleukin-2 intervention regimen (Continued)

			per cycle in equal divided doses in day 1 and 3 every 8 weeks (58 participants)			
8	Davey 2000	48 weeks	Dose: 7.5 miu Route: subcutaneous Duration: 6 cycles every 12 hours for 5 days every 8 weeks	ART not specified	CD4 cell count Viral load Adverse events	ART experienced
9	Dybul 2002	12 months	Dose: 7.5 miu Route: subcutaneous Duration: 3 cycles for 5 days every 8 week	ART not specified	CD4 cell count Viral load	Not specified
10	Hengge 1998	12 months	Dose: 9.6 miu Route: subcutaneous Duration: 5 cycles were given. One cycle was given every 6 weeks over a period of 52 weeks Treatment group A : subcutaneous administered daily in cycles consisting of 5 days Treatment group B: subcutaneous administered at a dose of 9.6 miu daily whenever CD4 counts dropped to below 1.25 fold of individual's baseline value	Saquinavir, lamivudine, and zidovudine	CD4 cell count Viral load Opportunistic infections	ART experienced
11	Katlama 2002	24 weeks with outcomes measured at weeks 1, 6, 12,	Dose: 4.5 miu Route: subcutaneous Duration: every 6	2 nucleoside analogues and one PI	CD4 cell count Viral load Adverse events	Not specified

Table 1. Details of the interleukin-2 intervention regimen (Continued)

		18, and 24	weeks for 4 cycles, every 12 hours for 5 days		ART experienced	
12	Kelleher 1998	48 weeks	Dose: 12 miu Route: intravenous Duration: Group A: 12.6 miu as continuous intravenous infusions for 5 days every 8 weeks for 6 cycles. Group B (IL-2 linked to polyethylene glycol plus ART): subcutaneous injections on days 1 and 3 of each 8-week cycles	ART included nucleoside analogues such as lamivudine	CD4 cell count Viral load	ART experienced
13	Kovacs 1996	14 months	Dose: 18 miu Route: intravenous Duration: daily for 5 days every other month for 6 cycles from month 0 to 10	ART included didanosine, zidovudine, zalcitabine, or stavudine	CD4 cell count Plasma HIV RNA	Not specified
14	Lalezari 2000	6 months	Dose: 1.2 miu, and then increased by 0.3 miu every 2 weeks for 6 months until a participant experienced grade 2 or greater toxicity Route: subcutaneous Duration: once daily for 2 weeks	ART not specified	CD4 cell count Viral load Adverse events	ART experienced
15	Levy 1999	14 months	Dose: 12 miu and 3 miu Route: 12 miu intravenous and 3 miu subcutaneous	Zidovudine (600 mg/day) plus didanosine (400 mg/day)	CD4 cell count Viral load Adverse events	ART naive

Table 1. Details of the interleukin-2 intervention regimen (Continued)

			intravenously (12 miu/day, N = 22) or subcutaneously (3 miu/m ² twice daily, N = 24) for 5 days, or 2 miu/m ² intravenous bolus, N = 22) administered every 2 months from week 2 to week 50 (7 cycles)			
16	Levy 2003	18 months	Dose: 5 miu Route: subcutaneous Duration: twice daily for a 5 day cycle given every 4 weeks for the first 3 cycles and then subsequently every 8 weeks for the next 7 cycles	ART included lamivudine (300 mg/day), stavudine (60 to 80mg/day) and indinavir (2400 mg/day)	CD4 cell counts Viral load AIDS defining events	ART naive or naive to PIs alone
17	Losso 2000	24 weeks	Dose: escalating doses of 1.5 miu, 4.5 miu, 7.5 miu Route: subcutaneous Duration: twice daily for 5 consecutive days every 8 weeks	ART not specified	CD4 cell counts Viral load	Both naive and experienced participants were included in the study
18	Marchetti 2002	48 weeks	Dose: 3 miu Route: subcutaneous Duration: administered as a single subcutaneous injection at days 1 to 5 and 8 to 12 of a 4-week cycle, for a total of 3 cycles	ART was either 2 nucleoside reverse transcriptase inhibitor and one PI or at least one non nucleoside reverse transcriptase inhibitor	CD4 cell count Viral load Adverse events	ART experienced
19	Marchetti 2004	48 weeks	Dose: 3 miu Route:	ART not specified	CD4 cell count	ART experienced

Table 1. Details of the interleukin-2 intervention regimen (Continued)

			subcutaneous Duration: administered at day 1 to 5 and 8 to 12 for 10 weeks			
20	Mitsuyasu 2007	84 weeks	Dose: Group A 9 miu and Group B 7.5miu Route: intravenous and subcutaneous Duration: Group A: intravenous infusions 5 days every 8 weeks Group B: subcutaneous injections 7.5 miu twice daily for 5 days every 8 weeks	Received ART alone, 2 nucleosides and a PI	CD4 cell count Viral load	Not specified
21	Ruxrungham 2000	24 weeks	Dose: Group A 1.5 miu, Group B 4.5 miu, and Group C 7.5 miu Route: subcutaneous Duration: twice daily for 5 days, every 8 weeks for three cycles 8-weekly	ART not specified	CD4 cell count Viral load	ART experienced
22	Stellbrink 2002	601 days	Dose: 9 miu Route: subcutaneous Duration: once daily (with an option to switch to 4.5 miu twice daily) for 5 consecutive days per cycle administered at 6-weekly intervals	ART consisting of stavudine 30 to 40 mg twice daily, and lamivudine 150 mg twice daily, nelfinavir 750 mg 3 times daily and saquinavir 600 mg 3 times daily	CD4 cell count Viral load	ART naive
23	Tambussi 2001	12 months	Dose: 3 regimens of IL-2	2 NRTIs and saquinavir	CD4 cell count Viral load	ART experienced

Table 1. Details of the interleukin-2 intervention regimen (Continued)

			<p>Route: intra-venous and sub-cutaneous</p> <p>Duration: dif-fered by group see details below</p> <p>Group A: 12 miu by continuous in-travenous in-fusion followed by subcutaneous 7.5 miu twice a day for 5 days every 8 weeks for the re-maining 4 cycles</p> <p>Group B: subcu-taneous 7.5 miu twice a day for 5 days every 8 weeks for 6 cycles</p> <p>Group C: sub-cutaneous 3 miu twice a day every 4 weeks</p>			
24	Tavel 2003	12 months	<p>Dose: 7.5 miu</p> <p>Route: subcutaneous</p> <p>Dura-tion: Group A: 7.5 miu twice daily for 5 days versus placebo plus ART</p> <p>Group B: 7.5 miu twice a day for 5 days</p>	Nucleosides ana-logue reverse tran-scriptase inhibitor and either a non-nucleosides ana-logue reverse tran-scriptase inhibitor or PI	CD4 cell count Viral load	ART experienced
25	Vogler 2004	24 weeks	<p>Dose: 1 miu</p> <p>Route: subcutaneous</p> <p>Duration: once daily</p>	2 nucleoside re-verse transcriptase inhibitors	CD4 cell count Viral load	ART experienced

Abbreviations: ART antiretroviral therapy; IL-2 Interleukin 2; NRTI nucleoside reverse transcriptase inhibitors; PI protease inhibitor

Table 2. Effect of intervention: change in CD4 count

Increase in CD4 cell count with statistically significant difference	
Abrams 2002 (at 12 months follow-up) n = 511	The average difference change in CD4 cell count between the IL-2 group and control group was 217.1 cells/mm ³ (95% CI 188.6 to 245.5; P < 0.001) measured at 12 months
Carr 1998 (at 12 months follow-up) n = 115	Median CD4 cell count increases of 359 and 44 cells/mm ³ and a decline of 46 cells/mm ³ in the cyclical continuous intravenous IL-2, subcutaneous IL-2, and ART alone group, respectively, over 12 months (P < 0.0001 for each intergroup comparison)
Davey 2000 (at 12 months follow-up) n = 82	The median increase in CD4 count at 12 months was 279 cells/mm ³ in the IL-2 group compared with 50 cells/mm ³ in the control (P < 0.001)
de Boer 2003 n = 81	The mean per cent increase in CD4 cell counts was 24.5% for IL-2 recipients compared to a mean per cent decrease of 30.5% for control participants (P < 0.005)
Hengge 1998 (at 12 months follow-up) n = 64	The median CD4 cell counts increased from 363 to 485 (+ 33.6% standard deviation) in the IL-2 group Group A (P < 0.01) and from 358 to 462 (+ 29.1%) in Group B (P < 0.01) and from 350 to 375 (+ 6.9% in the control group (not significant), respectively
Katlama 2002 (at 24 weeks, that is 6 months follow-up) n = 72	The median increase in CD4 cells at week 24 was significantly higher in the IL-2 group than in the control group (65 versus 18 cells/mm ³ ; P < 0.0001)
Kovacs 1996 (at 12 months follow-up) n = 60	There was an increase in the mean (\pm SE) CD4 count from 428 \pm 25 cells/mm ³ at baseline to 916 \pm 128 in the IL-2 group, compared to a decreased from 406 \pm 29 cells/mm ³ to 349 \pm 41 cells/mm ³ in the control group (P < 0.001).
Lalezari 2000 (at 26 weeks follow-up) n = 115	The percentage increase in CD4 count from baseline of 3.59% in the IL-2 group compared to 1.33% in the control group (P < 0.001)
Levy 1999 (at 56 weeks follow-up) n = 94	The median increase in CD4 count from baseline at 56 weeks was 564 cells/mm ³ (P > 0.0001), 105 cells/mm ³ (P = 0.58), and 676 cells/mm ³ (P = 0.0002) in the subcutaneous (SC), polyethylene glycol modified, and intravenous (IV) IL-2 group respectively, compared to 55 cells/mm ³ in the control group
Levy 2003 (at 74 weeks follow-up) n = 118	The median increase in CD4 count from baseline at week 865 cells/mm ³ in the IL-2 group compared to 262 cells/mm ³ in the control group (P < 0.00001)

Table 2. Effect of intervention: change in CD4 count (Continued)

<p>Losso 2000 (at 24 weeks follow-up) n = 73</p>	<p>The mean increase in CD4 count from baseline at week 24 of 27 cells/mm³ (P = 0.105), 105 cells/mm³ (P = 0.006), and 492 cells/mm³ (P < 0.001) in the 1.5, 4.5, and 7.5 miu dose groups of IL-2. Overall 14 out of 36 (41%) of the IL-2 group and 3 out of 37 (8%) of the controls had a magnitude increase of ≥ 1000 cells/mm³</p>
<p>Marchetti 2002 (48 weeks follow-up) n = 22</p>	<p>IL-2 treated participants had mean absolute CD4 T cell counts (S.E) significantly increase at the end of the IL-2 treatment (week 48) from 147 (18) cells/mm³ at baseline to 298 (43.3) cells/mm³ (P=0001). The control participants also had a significant increase was observed 16 weeks 228 (29) cells/mm³ (P = 0.002)</p>
<p>Mitsuyasu 2007 (at 48 weeks follow-up) n = 159</p>	<p>Reported median increases of CD4 cell count were 459, 312, and 102 cells/mm³ in the intravenous, SC IL-2, and control groups respectively at 48 weeks (P < 0.001 for both)</p>
<p>Tavel 2003 (at 12 months follow-up) n = 19</p>	<p>Reported a mean increase in CD4 count from baseline of 452 cells/mm³ in the IL-2 group compared to 135 cells/mm³ in the control group (P < 0.05).</p>
<p>Ruxrungtham 2000 n = 82</p>	<p>Reported an increase in the time weighted mean CD4 cell count 252 x 10⁶ cells/mm³ over 24 weeks for the overall scIL-2 group compared with 42 x 10⁶ cell/mm³.</p>
<p>Increase in CD4 cell count but statistical significance not reported in the trials</p>	
<p>Abrams 2009a (at 12 months follow-up) (at 6 years follow-up) n = 4111</p>	<p>Six trials measured at 1 year; median CD4 increase of 206 versus 21 cells/mm³ in the IL-2 group versus the control group and reported an average median increase of 109 more in the IL-2 group more than the control group over the entire 7 years (95% CI 40 to 60 over 6 years)</p>
<p>Abrams 2009b (at 12 months follow-up) n = 1695</p>	<p>Six trials measured at 1 year; median CD4 increase of 131 versus 32 cells/mm³ in the IL-2 group versus the control group over 12 months and reported an average median increase of 53 more in the IL-2 group more than the control group over the entire 7 years (95% CI 40 to 60 over 6 years)</p>
<p>Dybul 2002 (at 12 months follow-up) n = 9</p>	<p>Four participants treated with HAART plus 3 cycles of intermittent IL-2 had an increase in median absolute CD4+ T cell count from 529 cells/mm³ (range: 502 to 738 cells/mm³) at enrolment to 1995 cells/mm³ (range: 1112 to 3064 cells/mm³; 268% increase) after 12 months of treatment (Figure 1A). Five participants treated with HAART alone had an increase in median CD4+ T cell count from 580 cells/mm³ (range: 416 to 662 cells) at enrolment to 712 cells/mm³ (range: 667 to 1160 cells/mm³; 52% increase) after 12 months of treatment</p>

Table 2. Effect of intervention: change in CD4 count (Continued)

No significant increase in CD4 cell count	
Vogler 2004 (at 24 weeks) n = 115	Mean change in CD4 count in the IL-2 group and the control group was 40 and -1 respectively
Tambussi 2001 n = 61	Reports that there was a progressive increase in circulating CD4 cells, determined at the beginning of each IL-2 cycle, was observed in all participants receiving ART plus IL-2, in comparison with those receiving ART alone but gave the values for the within sub-group variation
Amendola 2000 (at 6 months follow-up) n = 22	No significant difference between changes in CD4 counts in both groups

Abbreviations: ART: antiretroviral therapy; ESPIRIT: Evaluation of Subcutaneous Proleukin in a Randomised International Trial; IL-2: interleukin-2; SILICAAT: subcutaneous recombinant human interleukin-2 in HIV-infected patients low CD4 counts under active antiretroviral therapy

APPENDICES

Appendix I. CENTRAL search strategy

Date: 26 May 2016

ID	Search	Hits
#1	MeSH descriptor: [HIV Infections] explode all trees	8930
#2	MeSH descriptor: [HIV] explode all trees	2820
#3	hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or (hiv near infect*) or (human immunodeficiency virus) or (human immunodeficiency virus) or (human immune-deficiency virus) or (human immuno-deficiency virus) or (human immune deficiency virus) or (human immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunodeficiency syndrome) or (acquired immuno-deficiency syndrome) or (acquired immune-deficiency syndrome) or (acquired immun* deficiency syndrome) (Word variations have been searched)	16171

(Continued)

#4	MeSH descriptor: [Lymphoma, AIDS-Related] this term only	23
#5	MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only	25
#6	#1 or #2 or #3 or #4 or #5	16256
#7	MeSH descriptor: [Antiretroviral Therapy, Highly Active] this term only	1161
#8	MeSH descriptor: [Anti-HIV Agents] explode all trees	3013
#9	MeSH descriptor: [Antiviral Agents] this term only	3778
#10	MeSH descriptor: [AIDS Vaccines] this term only	371
#11	anti hiv or antiretroviral* or anti retroviral* or AIDS vaccin*	7521
#12	#7 or #8 or #9 or #10 or #11	11280
#13	#6 and #12	7996
#14	MeSH descriptor: [Interleukin-2] explode all trees	848
#15	“interleukin 2”:ti,ab or IL2:ti,ab or IL-2:ti,ab aldesleukin:ti,ab or proleukin:ti,ab or “interleukin II”:ti,ab or interleukin2:ti,ab or “interleukine 2”:ti,ab (Word variations have been searched)	1526
#16	#14 or #15	1794
#17	#13 and #16	144

Appendix 2. MEDLINE search strategy

Date: 26 May 2016

Search	Query	Items found
#8	Search (#3 AND #4 AND #7)	634
#7	Search (#5 OR #6)	69303
#6	Search (interleukin 2[tiab] OR interleukin2[tiab] OR IL2[tiab] OR IL-2[tiab] OR aldesleukin[tiab] OR proleukin[tiab] OR interleukin II[tiab] OR interleukine 2[tiab])	62977

(Continued)

#5	Search interleukin-2[mh]	36542
#4	Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])	3285304
#3	Search (#1 AND #2)	99540
#2	Search (antiretroviral therapy, highly active[MeSH] OR antiretroviral agents[MeSH] OR antiviral agents[MeSH:NoExp] OR ((anti[tiab]) AND (hiv[tiab])) OR antiretroviral*[tiab] OR ((anti[tiab]) AND (retroviral*[tiab])) OR HAART[tiab] OR ((anti[tiab]) AND (acquired immunodeficiency[tiab])) OR ((anti[tiab]) AND (acquired immuno-deficiency[tiab])) OR ((anti[tiab]) AND (acquired immune-deficiency[tiab])) OR ((anti[tiab]) AND (acquired immun*[tiab]) AND (deficiency[tiab]))	157998
#1	Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunodeficiency virus[tiab] OR human immuno-deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunodeficiency syndrome[tiab] OR acquired immuno-deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency syndrome[tiab])) OR "sexually transmitted diseases, Viral"[MeSH:NoExp])	344877

Appendix 3. Embase search strategy

Date: 26 May 2016

No.	Query	Results
#11	#3 AND #9 AND #10	318
#10	'interleukin 2'/syn OR interleukin2:ab,ti OR 'aldesleukin'/syn OR 'proleukin'/syn OR il2 OR 'il+2'/syn OR 'interleukin ii'/syn OR 'interleukine 2'	117687
#9	#4 NOT #8	1615894

(Continued)

#8	#5 NOT #7	5350278
#7	#5 AND #6	1470137
#6	'human'/de OR 'normal human'/de OR 'human cell'/de	17154813
#5	'animal'/de OR 'animal experiment'/de OR 'invertebrate'/de OR 'animal tissue'/de OR 'animal cell'/de OR 'nonhuman'/de	6820415
#4	'randomized controlled trial'/de OR 'randomized controlled trial' OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR factorial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volunteer*:ab,ti OR 'crossover procedure'/de OR 'crossover procedure' OR 'double-blind procedure'/de OR 'double-blind procedure' OR 'single-blind procedure'/de OR 'single-blind procedure' OR (doubl* NEAR/3 blind*):ab,ti OR (singl*:ab,ti AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:ab,ti OR (cross NEXT/1 over*):ab,ti	1811081
#3	#1 AND #2	140652
#2	'human immunodeficiency virus vaccine'/exp OR 'human immunodeficiency virus vaccine' OR 'human immunodeficiency virus vaccine':ab,ti OR 'anti human immunodeficiency':ab,ti OR 'anti human immunodeficiency':ab,ti OR 'anti human immunodeficiency':ab,ti OR 'anti human immunodeficiency':ab,ti OR 'anti acquired immune-deficiency':ab,ti OR 'anti acquired immunodeficiency':ab,ti OR 'anti acquired immunodeficiency':ab,ti OR 'anti acquired immunodeficiency':ab,ti OR 'anti hiv':ab,ti OR antiretrovir*:ab,ti OR 'anti retroviral':ab,ti OR 'anti retrovirals':ab,ti OR 'anti retrovirus':ab,ti OR haart:ab,ti OR 'aids vaccine':ab,ti OR 'aids vaccines':ab,ti OR 'anti human immunodeficiency virus agent'/exp OR 'anti human immunodeficiency virus agent' OR 'antiretrovirus agent'/exp OR 'antiretrovirus agent' OR 'antiretrovirus agent':ab,ti OR 'highly active antiretroviral therapy'/exp OR 'highly active antiretroviral therapy' OR 'highly active antiretroviral therapy':ab,ti	196031
#1	'human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus infection'/de OR 'human immunodeficiency virus infection' OR 'human immunodeficiency virus'/exp OR 'human immunodeficiency virus'/de OR 'human immunodeficiency virus' OR 'human immunodeficiency virus':ab,ti OR hiv:ab,ti OR 'hiv-1':ab,ti OR 'hiv-2':ab,ti OR 'human immunodeficiency virus':ab,ti OR 'human immunodeficiency virus':ab,ti OR 'human immune-deficiency virus':ab,ti OR 'human immuno-deficiency virus':ab,ti OR 'acquired	446717

(Continued)

immunodeficiency syndrome':ab,ti OR 'acquired immuno-
deficiency syndrome':ab,ti OR 'acquired immune-deficiency
syndrome':ab,ti OR 'acquired immunodeficiency syndrome':
ab,ti

Appendix 4. ClinicalTrials.gov search strategy

Search strategy: HIV AND (“interleukin-2” OR “interleukin 2” OR aldesleukin OR proleukin OR “interleukin II”) | Interventional Studies | received from 11/14/2014 to 05/26/2016

CONTRIBUTIONS OF AUTHORS

Jennifer Onwumeh and Charles Okwundu wrote the draft protocol and review, independently performed the study selection and data extraction. Tamara Kredo contributed to the protocol, gave input into the manuscript, analysis and the final review.

DECLARATIONS OF INTEREST

Jennifer Onwumeh, Charles Okwundu, and Tamara Kredo have no known conflicts of interest with respect to this review.

SOURCES OF SUPPORT

Internal sources

- Centre for Evidence-Based Health Care, Stellenbosch University, South Africa.
- Liverpool School of Tropical Medicine, UK.

External sources

- Department for International Development, UK.
Grant: 5242

INDEX TERMS

Medical Subject Headings (MeSH)

AIDS-Related Opportunistic Infections [epidemiology]; Anti-Retroviral Agents [adverse effects; *therapeutic use]; CD4 Lymphocyte Count; Cause of Death; Chemotherapy, Adjuvant; HIV Infections [blood; drug therapy; mortality]; HIV Seropositivity [blood; *drug therapy; mortality]; Interleukin-2 [adverse effects; *therapeutic use]; RNA, Viral [blood]; Randomized Controlled Trials as Topic; Viral Load

MeSH check words

Adult; Humans